US20090234214A1 - Multi-reservoir device and method for transdermal sensing - Google Patents
Multi-reservoir device and method for transdermal sensing Download PDFInfo
- Publication number
- US20090234214A1 US20090234214A1 US12/471,973 US47197309A US2009234214A1 US 20090234214 A1 US20090234214 A1 US 20090234214A1 US 47197309 A US47197309 A US 47197309A US 2009234214 A1 US2009234214 A1 US 2009234214A1
- Authority
- US
- United States
- Prior art keywords
- reservoir
- drug
- skin
- reservoirs
- transporting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00642—Plasters form or structure soluble, e.g. in water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Definitions
- This invention is generally in the field of devices and methods for the transdermal drug delivery and analyte sensing.
- Transdermal drug delivery systems generally rely on diffusion of drug across the skin.
- the transdermal drug delivery system is in the form of a multi-layered patch that includes a backing or cover layer, a drug matrix/reservoir, a diffusion control membrane, and an adhesive layer for attaching the system to the surface of the skin.
- drugs delivered with such systems include scopolamine (Trasderm-ScopTM), nicotine, nitroglycerin (Nitro-DurTM), estradiol (EstradermTM), and testosterone.
- transdermal patches generally are unsuitable for delivery of macromolecules.
- transdermal and other drug delivery systems it is generally desirable to store and protect the drug formulation until the time it is to be delivered to a patient, because exposure to environmental components (e.g., oxygen, humidity) may damage or prematurely degrade the pharmaceutical agent.
- environmental components e.g., oxygen, humidity
- the entire drug formulation is contained in a single reservoir, such that is it not possible to protect or isolate individual doses. It would be desirable to be able to do so, particularly for relatively fragile pharmaceutical agent molecules.
- the device includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps that prevent the pharmaceutical agent from passing out from the reservoirs, control means for actuating release of the pharmaceutical agent from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, means for securing the device to the skin of the patient, and means for transporting to the skin the one or more pharmaceutical agents following release from the one or more of the reservoir.
- the device includes a housing which contains the substrate, reservoirs, control means, and a power source.
- the device further includes a removably attachable electronics portion which comprises the power source and at least a portion of the control means.
- the reservoir cap is formed of an electrically conductive material and the control means comprises an electrical input lead connected to said reservoir cap, an electrical output lead connected to said reservoir cap, wherein the reservoir cap is disintegrated by application of an electrical current through the reservoir cap via the input lead and output lead.
- the device may further include a source of electric power, such as a battery or capacitor, for applying the electrical current.
- the reservoirs are microreservoirs.
- the reservoir cap comprises a metal film.
- the means for securing the device comprises a pressure sensitive adhesive. In one embodiment, the means for securing comprises an adhesive layer that is permeable to the pharmaceutical agent or analyte.
- the means for transporting includes a transport medium disposed between the reservoir caps and the skin.
- the transport medium can include a permeable body through which the pharmaceutical agent released from the reservoirs can diffuse.
- the transport medium comprises a reservoir containing a liquid, gel, or semi-solid permeation material.
- the means for transporting comprises a plurality of microneedles.
- the means for transporting comprises one or more chemical penetration enhancers.
- the means for transporting comprises means for effecting iontophoresis, electroosmosis, or electroporation.
- the means for transporting comprises an ultrasound generator.
- the means for transporting comprises a heating element.
- the means for transporting comprises a flexible or rigid member having media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- the one or more pharmaceutical agents include a drug selected from among androgen, estrogen, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti-depressants, antibiotics, anti-cancer agents, local anesthetics, antiemetics, anti-infectants, contraceptives, anti-diabetic agents, steroids, anti-allergy agents, anti-migraine agents, agents for smoking cessation, anti-obesity agents, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progestrone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, and combinations thereof.
- a drug selected from among androgen, estrogen, non-steroidal anti-inflammatory agents, anti-hypertensive agents, anal
- a medical device for transdermal administration of one or more pharmaceutical agents to a patient in need thereof, which includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps which prevent the one or more pharmaceutical agents from passing out from the reservoirs, control means for actuating release of the one or more pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, an adhesive or strap material for securing the device to the skin of the patient, and a body defining a transport medium reservoir disposed between the reservoir caps and the skin of the patient, the body and reservoir facilitating transport of the pharmaceutical agent to the skin following its release from one or more of the reservoir.
- the transport medium reservoir contains a liquid, gel, or semi-solid permeation material.
- the transport medium reservoir comprises a single pool of a biocompatible transport fluid into which the pharmaceutical agent is diluted prior to delivery to the skin.
- the transport medium reservoir comprises individual channels for delivery of the pharmaceutical agent with no or minimal dilution prior to delivery to the skin.
- a device for sensing an analyte in a human or other animal.
- the device includes a substrate; a plurality of discrete reservoirs in the substrate, the reservoirs having at least one opening; one or more sensors or diagnostic agents stored in the reservoirs; discrete reservoir caps which cover said at least one opening; control means for disintegrating or permeabilizing the reservoir caps; means for securing the device to the skin of the patient; and means for transporting an analyte from the skin to the one or more sensors or for transporting the one or more diagnostic agents to the skin following release of said diagnostic agents from the one or more of the reservoir.
- FIG. 1 is a cross-sectional view of one embodiment of the medical device for transdermal drug delivery or analyte sensing described herein.
- FIGS. 2A and 2B are a perspective view ( FIG. 2A ) and a cross-sectional view ( FIG. 2B ) of another embodiment of the medical device for transdermal drug delivery or analyte sensing described herein.
- FIG. 3 is a perspective, cross-sectional view of one embodiment of the reservoir and body portion of the drug delivery or sensing device described herein.
- FIG. 4 is a schematic of the operation of one embodiment of the control means for the medical device for transdermal drug delivery or analyte sensing described herein.
- FIG. 5 is a cross-sectional view of one portion of one embodiment of the device shown in FIG. 1 , showing one reservoir pre-actuation and one reservoir post-actuation.
- FIG. 6 is a cross-sectional view of one embodiment of the medical device for transdermal drug delivery or analyte sensing that includes microneedles.
- Medical devices have been developed for the transdermal administration of one or more pharmaceutical agents to patient in need thereof, or for analyte sensing/diagnostics.
- the devices isolate each dose or portions of a dose of the pharmaceutical agent within multiple individual (discrete) reservoirs, which typically are arrayed in/across a body portion of the device.
- the isolated doses or partial doses are protected from environmental components that may damage or prematurely degrade the pharmaceutical agent or other reservoir contents, until the desired time for release or exposure of the pharmaceutical agent or other reservoir contents.
- the Medical Device The Medical Device
- the device comprises a substrate; a plurality of discrete reservoirs in the substrate; one or more pharmaceutical agents stored in the reservoirs; discrete reservoir caps that prevent the one or more pharmaceutical agents from passing out from the reservoirs; control means for actuating release of the pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps; means for securing the device to the skin of the patient; and means for transporting the pharmaceutical agent to the skin following release from one or more of the reservoirs.
- the device is used to deliver a diagnostic agent into the skin.
- the agent could be a small molecule metabolite reporter, used in glucose detecting.
- the device is not used to deliver something but to contain a plurality of sensors for selective exposure.
- the device could be adapted to sense an analyte withdrawn, either by passive or active mechanisms, from or through the skin.
- the device comprises a substrate, i.e., a body portion, that includes the plurality of discrete reservoirs, e.g., in the form of a two-dimensional array of selectively spaced reservoirs—located in discrete positions—across at least one surface of the body portion.
- a reservoir is a well, a recess, a hole or a cavity, located in a solid structure and suitable for containing a quantity of another material and/or a secondary device.
- the body portion comprises silicon, a metal, a ceramic, a polymer, or a combination thereof.
- suitable substrate materials include metals, ceramics, semiconductors, glasses, and degradable and non-degradable polymers.
- each reservoir is formed of hermetic materials (e.g., metals, silicon, glasses, ceramics) and is hermetically sealed by at least one reservoir cap. In one case, if the reservoir has a second opening, distal the reservoir cap-sealed opening, then a hermetic seal can be formed at that distal opening as well, in order for the reservoir contents to be hermetically isolated within the reservoir.
- each can be covered by a reservoir cap which can be opened for release or exposure of the reservoir contents.
- a reservoir can have two or more separate openings on the same side of the reservoir, which can be covered by one or two or more discrete reservoir caps.
- the reservoirs can be in essentially any shape, and typically are shaped to facilitate reservoir manufacture and loading of contents, as well as packing of reservoirs into the substrate.
- the substrate can have a variety of shapes, or shaped surfaces. It can, for example, have a release side (i.e., an area having reservoir caps) that is planar or curved.
- the substrate may, for example, be in a shape selected from circular, square, or ovoid disks.
- the release side can be shaped to conform to a curved tissue surface.
- the device body can be flexible or rigid. In one embodiment, the device flexibly conforms to a tissue surface as taught in U.S. Patent Application Publication No. 2002/0099359 to Santini et al., which is incorporated herein by reference.
- the substrate may consist of only one material, or may be a composite or multi-laminate structure, that is, composed of several layers of the same or different substrate materials bonded or fused together.
- the substrate comprises layers of silicon and Pyrex bonded together.
- the substrate comprises multiple silicon wafers bonded together.
- the substrate comprises a low-temperature co-fired ceramic (LTCC).
- LTCC low-temperature co-fired ceramic
- the body portion is the substrate of a microchip device. In one example, this substrate is formed of silicon.
- the substrate is formed from one or more polymers, copolymers, or blends thereof.
- the reservoirs need not be defined/enclosed by hermetic materials, particularly where the time the reservoir contents are isolated is relatively short, for example, when the transdermal device is used only for a period of a few days (e.g., less than 2 days, less than 3 days).
- polymeric substrates may be preferred, particularly because they can be less costly to manufacture than some silicon or ceramic substrate devices.
- the polymeric substrate can be easily made to conform to a particular skin surface area of the human or animal body.
- the reservoirs are microreservoirs.
- microreservoir refers to a discrete hole or concave-shaped space in a solid structure suitable for releasably containing a material.
- the structure is of a size and shape suitable for filling with a microquantity of the material, which comprises a drug.
- the microreservoir has a volume equal to or less than 500 ⁇ L (e.g., less than 250 ⁇ L, less than 100 ⁇ L, less than 50 ⁇ L, less than 25 ⁇ L, less than 10 ⁇ L, etc.) and greater than about 1 nL (e.g., greater than 5 nL, greater than 10 nL, greater than about 25 nL, greater than about 50 nL, greater than about 1 ⁇ L, etc.).
- the shape and dimensions of the microreservoir can be selected to maximize or minimize contact area between the drug material and the surrounding surface of the microreservoir.
- the term “microquantity” refers to small volumes between 1 nL and 500 ⁇ L. In one embodiment, the microquantity is between 1 nL and 1 ⁇ L. In another embodiment, the microquantity is between 10 nL and 500 nL.
- Microreservoirs can be fabricated in a structural body portion using fabrication techniques known in the art.
- Representative fabrication techniques include MEMS fabrication processes or other micromachining processes, various drilling techniques (e.g., laser, mechanical, and ultrasonic drilling, electrical discharge machining (EDM)), and build-up techniques, such as LTCC (low temperature co-fired ceramics), punch- or embossing-type processes, thin film or tape processes.
- the surface of the microreservoir optionally can be treated or coated to alter one or more properties of the surface. Examples of such properties include hydrophilicity/hydrophobicity, wetting properties (surface energies, contact angles, etc.), surface roughness, electrical charge, release characteristics, biocompatibility, and the like.
- the coating material also can be selected to affect biostability or tissue interactions with the device or with the reservoir contents.
- Other fabrication processes particularly ones useful with polymeric substrates, can be used, including injection molding, thermal compression molding, extrusion, embossing, solvent casting, and other polymer forming techniques known in the art. See also U.S. Patent Application Publication No. 2002/0107470 A1 to Richards, et al., which is incorporated herein by reference.
- the reservoirs are larger than microreservoirs and can contain a quantity of drug formulation larger than a microquantity.
- the volume of each reservoir can be greater than 10 ⁇ L (e.g., at least 20 ⁇ L, at least 50 ⁇ L, at least 100 ⁇ L, at least 250 ⁇ L, etc.) and less than 10 mL (e.g., less than 5 mL, less than 1000 ⁇ L, less than 500 ⁇ L, less than 300 ⁇ L, etc.).
- macro-reservoirs and macro-quantities respectively.
- the term “reservoir” is intended to include both.
- Total substrate thickness and reservoir volume can be increased by bonding or attaching wafers or layers of substrate materials together.
- the device thickness may affect the volume of each reservoir and/or may affect the maximum number of reservoirs that can be incorporated onto a substrate.
- the size and number of substrates and reservoirs can be selected to accommodate the quantity and volume of reservoir contents needed for a particular application, manufacturing limitations, and/or total device size limitations suitable for reasonably comfortable attachment to a patient's skin.
- Different device thicknesses may be chosen, depending for example of the type of application. For example, in sensing/diagnostic applications, the thickness may impact analyte transport and thus sensor response. Accordingly, it may be useful to provide a relatively thin substrate for certain sensing devices. As another example, in drug delivery applications, thicker substrates may be desired in order to increase reservoir depth and volume to contain more drug formulation, enabling increased dosage loading.
- the substrate has at least two, or preferably many, discrete reservoirs. In various embodiments, tens, hundreds, or thousands of reservoirs are arrayed across the substrate.
- the device could include between 50 and 250 reservoirs, where each reservoir contains a single dose of a drug for release, which for example could be released hourly or daily over a period of several days.
- the present multi-reservoir devices can readily store and delivery different drug formulations from a single device. For example, different reservoirs could contain different drugs, or different reservoirs could contain different dosages or concentrations of the same drug.
- the device comprises a microchip chemical delivery device, as taught in U.S. Pat. No. 5,7979,898, which is incorporated herein by reference.
- the device could include polymeric chips or devices, as well other devices containing arrays of reservoirs, composed of non-silicon based materials that might not be referred to as “microchips.”
- any pharmaceutical agent i.e., therapeutic or prophylactic agent (e.g., an active pharmaceutical ingredient or API), suitable for transdermal administration can be used with the device described herein.
- the present devices would be particularly useful for the storage and delivery of drugs that currently are not suitable for use with conventional transdermal systems due to instability issues associated with the drug.
- a drug or drug formulation that is easily degradable could be protected until needed using the multiple reservoirs, each of which can be hermetically sealed until ruptured when needed to release the drug contained therein. In this way, only the quantity of the drug needed at a particular time is exposed; the remaining drug remains stored and protected.
- the device can deliver a single pharmaceutical agent or a combination of pharmaceutical agents, which can be stored together in the same reservoir or stored in separate reservoirs.
- the device and formulation may be tailored to deliver the active ingredient locally or systemically.
- the pharmaceutical agent (also referred to herein as a drug) can be provided in the reservoirs in a solid, liquid, semi-solid, solution, or suspension, or emulsion formulation. It can be in a pure form or combined with one or more excipient materials.
- pure form of the drug includes the API, residual moisture, and any chemical species combined with the API in a specific molar ratio that is isolated with the API during preparation of the API (for instance, a counter-ion) and which has not been added as an excipient.
- the drug is formulated in a matrix form, comprising a matrix material in which the drug is contained or dispersed.
- the matrix material further controls release of the drug by controlling dissolution and/or diffusion of the drug from the reservoir, and may enhance stability of the drug molecule while stored in the reservoir.
- the drug is formulated with an excipient material that is useful for accelerating release, e.g., a water-swellable material that can aid in pushing the drug out of the reservoir and through any tissue capsule over the reservoir.
- excipient material that is useful for accelerating release
- examples include hydrogels and osmotic pressure generating agents known in the art.
- the drug is formulated with a penetration enhancer(s).
- the penetration enhancer(s) further controls release of the drug by facilitating transport of the drug across the skin into the local administration site or systemic delivery.
- the drug can comprise small molecules, large (i.e., macro-) molecules, or a combination thereof.
- the large molecule drug is a protein or a peptide.
- the drug can be selected from amino acids, vaccines, antiviral agents, gene delivery vectors, interleukin inhibitors, immunomodulators, neurotropic factors, neuroprotective agents, antineoplastic agents, chemotherapeutic agents, polysaccharides, anti-coagulants (e.g., LMWH, pentasaccharides), antibiotics (e.g., immunosuppressants), analgesic agents, and vitamins.
- the drug is a protein.
- suitable types of proteins include glycoproteins, enzymes (e.g., proteolytic enzymes), hormones or other analogs (e.g., LHRH, steroids, corticosteroids, growth factors), antibodies (e.g., anti-VEGF antibodies, tumor necrosis factor inhibitors), cytokines (e.g., ⁇ -, ⁇ -, or ⁇ -interferons), interleukins (e.g., IL-2, IL-10), and diabetes/obesity-related therapeutics (e.g., insulin, exenatide, PYY, GLP-1 and its analogs).
- enzymes e.g., proteolytic enzymes
- hormones or other analogs e.g., LHRH, steroids, corticosteroids, growth factors
- antibodies e.g., anti-VEGF antibodies, tumor necrosis factor inhibitors
- cytokines e.g., ⁇ -, ⁇ -, or ⁇ -interferons
- the drug is a gonadotropin-releasing (LHRH) hormone analog, such as leuprolide.
- the drug comprises parathyroid hormone, such as a human parathyroid hormone or its analogs, e.g., hPTH(1-84) or hPTH(1-34).
- the drug is selected from nucleosides, nucleotides, and analogs and conjugates thereof.
- the drug comprises a peptide with natriuretic activity, such as atrial natriuretic peptide (ANP), B-type (or brain) natriuretic peptide (BNP), C-type natriuretic peptide (CNP), or dendroaspis natriuretic peptide (DNP).
- the drug is selected from diuretics, vasodilators, inotropic agents, anti-arrhythmic agents, Ca + channel blocking agents, anti-adrenergics/sympatholytics, and renin angiotensin system antagonists.
- the drug is a VEGF inhibitor, VEGF antibody, VEGF antibody fragment, or another anti-angiogenic agent.
- VEGF inhibitor VEGF antibody
- VEGF antibody fragment VEGF antibody fragment
- another anti-angiogenic agent examples include an aptamer, such as MACUGENTM (Pfizer/Eyetech) (pegaptanib sodium)) or LUCENTISTM (Genetech/Novartis) (rhuFab VEGF, or ranibizumab), which could be used in the prevention of choroidal neovascularization.
- the drug is a prostaglandin, a prostacyclin, or another drug effective in the treatment of peripheral vascular disease.
- the device delivers one or more drugs known in the art for use in pain management.
- drugs include lidocaine and fentanyl.
- the drug is an anti-inflammatory, such as dexamethasone.
- the drug is an anti-emetic, such as a 5HT-5 antagonist.
- the drug is a NSAID, such as ketaprofen.
- the drug is an anti-anxiety drug, such as benzodiazepines.
- the drug is a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor).
- the drug is an anticoagulant, such as warfarin, heparin, LMWH, oligo-asaccharides such as idraparinux and fondaparinux, and ximelagatran.
- the drug is an angiogenic agent, such as VEGF.
- a device includes both angiogenic agents and anti-inflammatory agents.
- the drug is a bone morphogenic protein, a growth factor, or a growth or differentiation factor.
- the reservoirs in one device can include a single drug or a combination of two or more drugs, and can further include one or more pharmaceutically acceptable carriers. Two or more can be stored together and released from the same one or more reservoirs or they can each be stored in and released from different reservoirs.
- oligonucleotide drugs may be delivered with the aid of iontophoresis or electroporation.
- Drugs that may be delivered using the devices and methods described herein include those listed in Table 1 below.
- the drug can be dispersed in a matrix material, to further control the rate of release of drug.
- This matrix material can be a “release system,” as described in U.S. Pat. No. 5,797,898, the degradation, dissolution, or diffusion properties of which can provide a method for controlling the release rate of the chemical molecules.
- the release system may provide a temporally modulated release profile (e.g., pulsatile release) when time variation in plasma levels is desired or a more continuous or consistent release profile when a constant plasma level as needed to enhance a therapeutic effect, for example.
- Pulsatile release can be achieved from an individual reservoir, from a plurality of reservoirs, or a combination thereof. For example, where each reservoir provides only a single pulse, multiple pulses (i.e., pulsatile release) are achieved by temporally staggering the single pulse release from each of several reservoirs. Alternatively, multiple pulses can be achieved from a single reservoir by incorporating several layers of a release system and other materials into a single reservoir.
- Continuous release can be achieved by incorporating a release system that degrades, dissolves, or allows diffusion of molecules through it over an extended period.
- continuous release can be approximated by releasing several pulses of molecules in rapid succession (“digital” release).
- the active release systems described herein can be used alone or on combination with passive release systems, for example, as described in U.S. Pat. No. 5,797,898.
- the reservoir cap can be removed by active means to expose a passive release system, or a given substrate can include both passive and active release reservoirs.
- the drug formulation within a reservoir comprises layers of drug and non-drug material. After the active release mechanism has exposed the reservoir contents, the multiple layers provide multiple pulses of drug release due to intervening layers of non-drug. In another variation, the same layering system could be used in device operating by passive release.
- the pharmaceutical agent can be formulated with one or more pharmaceutically acceptable excipients.
- Representative examples include bulking agents, wetting agents, stabilizers, crystal growth inhibitors, antioxidants, antimicrobials, preservatives, buffering agents (e.g., acids, bases), surfactants, desiccants, dispersants, osmotic agents, binders (e.g., starch, gelatin), disintegrants (e.g., celluloses), glidants (e.g., talc), diluents (e.g., lactose, dicalcium phosphate), color agents, lubricants (e.g., magnesium stearate, hydrogenated vegetable oils) and combinations thereof.
- buffering agents e.g., acids, bases
- surfactants desiccants
- dispersants e.g., osmotic agents
- binders e.g., starch, gelatin
- disintegrants e.g., celluloses
- the excipient is a wax or a polymer.
- the polymer comprises polyethylene glycol (PEG), e.g., typically one having a molecular weight between about 100 and 10,000 Daltons (e.g., PEG 200, PEG 1450).
- the polymer comprises poly lactic acid (PLA), poly glycolic acid (PGA), copolymers thereof (PLGA), or ethyl-vinyl acetate (EVA) polymers.
- the excipient material comprises a pharmaceutically acceptable oil (e.g., sesame oil).
- the excipient material includes a saturated drug solution. That is, the excipient material comprises a liquid solution formed of the drug dissolved in a solvent for the drug. The solution is saturated so that the solvent does not dissolve the solid matrix form of the drug. The saturated solution acts as a non-solvent excipient material, substantially filling pores and voids in the solid matrix.
- the excipient material comprises a pharmaceutically-acceptable perhalohydrocarbon or unsubstituted saturated hydrocarbon.
- a pharmaceutically-acceptable perhalohydrocarbon or unsubstituted saturated hydrocarbon See, for example, U.S. Pat. No. 6,264,990 to Knepp et al., which describes anhydrous, aprotic, hydrophobic, non-polar liquids, such as biocompatible perhalohydrocarbons or unsubstituted saturated hydrocarbons, such as perfluorodecalin, perflurobutylamine, perfluorotripropylamine, perfluoro-N-methyldecahydroquindine, perfluoro-octohydro quinolidine, perfluoro-N-cyclohexylpyrilidine, perfluoro-N,N-dimethylcyclohexyl methylamine, perfluoro-dimethyl-adamantane, perfluorotri-methylbicyclo (3.3.1) non
- the pharmaceutically acceptable excipient material comprises dimethyl sulfoxide (DMSO), glycerol, or ethanol.
- the excipient material can be one that would not ordinarily be considered as ingredient in a dosage form.
- the implantable drug delivery device comprises one or more discrete reservoirs of small volume, e.g., microreservoirs
- organic solvents that are not possible to use in large amounts, for example due to toxicity concerns.
- the solvents listed in Table 2 can be used as the excipient material if the device reservoir volumes are small enough to ensure that the daily exposure to the excipient cannot exceed predetermined limits, for example described in ICH Guideline Q 3 C: Impurities: Residual Solvents.
- the device includes structural components for controlling the time at which release of the pharmaceutical agent from the reservoir is initiated. These components include reservoir caps and reservoir control means.
- the control means includes control circuitry, which includes the hardware, electrical components, and software needed to control and deliver electric energy from a power source to selected reservoir(s) for actuation, e.g., reservoir opening.
- the term “reservoir cap” includes a membrane or other structure suitable for separating the contents of a reservoir from the environment outside of the reservoir. It generally is self-supporting across the reservoir opening, although caps having additional structures to provide mechanical support to the cap can be fabricated. See, e.g., U.S. Patent Application Publication Nos. 2002/0183721 A1, which is incorporated herein by reference. Selectively removing the reservoir cap or making it permeable will then “expose” the contents of the reservoir to the environment (or selected components thereof) surrounding the reservoir. In preferred embodiments, the reservoir cap is selectively disintegrated.
- the term “disintegrate” includes degrading, dissolving, rupturing, fracturing or some other form of mechanical failure, as well as a loss of structural integrity due to a chemical reaction (e.g., electrochemical degradation) or phase change (e.g., melting) in response to a change in temperature, unless a specific one of these mechanisms is indicated.
- the “disintegration” is by an electrochemical activation technique, such as described in U.S. Pat. No. 5,797,898.
- the “disintegration” is by an electro-thermal ablation technique, as described in U.S. Patent Application Publication No. 2004/0121486 A1 to Uhland et al., which is incorporated herein by reference in its entirety.
- the reservoir cap is a thin metal film and is impermeable to the surrounding environment (e.g., body fluids or another chloride containing solution).
- a particular electric potential is applied to the metal reservoir cap, which is then oxidized and disintegrated by an electrochemical reaction, to release the drug from the reservoir.
- suitable reservoir cap materials include gold, silver, copper, and zinc.
- the reservoir cap is heated (e.g., using resistive heating) to cause the reservoir cap to melt and be displaced from the reservoir to open it. See U.S. Pat. No. 6,527,762, which is incorporated herein by reference.
- This latter variation could be used, for example, with reservoir caps formed of a metal or a non-metal material, e.g., a polymer.
- the reservoir cap is formed of a polymer or other material that undergoes a temperature-dependent change in permeability such that upon heating to a pre-selected temperature, the reservoir is rendered permeable to the drug and bodily fluids to permit the drug to be released from the reservoir through the reservoir cap.
- the reservoir cap is formed of a conductive material, such as a metal film, through which an electrical current can be passed to electrothermally ablate it, as described in U.S. Patent Application Publication No. 2004/0121486 A1 to Uhland et al.
- suitable reservoir cap materials include gold, copper, aluminum, silver, platinum, titanium, palladium, various alloys (e.g., Au—Si, Au—Ge, Pt—Ir, Ni—Ti, Pt—Si, SS 304, SS 316), and silicon doped with an impurity to modulate the conductivity/resistivity because one can use the impurity to increase or decrease the conductivity or resistivity of the silicon, as known in the art.
- the reservoir cap is in the form of a thin metal film.
- the reservoir cap is part of a multiple layer structure, for example, the reservoir cap can be made of multiple metal layers, such as a multi-layer/laminate structure of platinum/titanium/platinum.
- the reservoir cap is operably (i.e., electrically) connected to an electrical input lead and to an electrical output lead, to facilitate flow of an electrical current through the reservoir cap.
- an effective amount of an electrical current is applied through the leads and reservoir cap, the temperature of the reservoir cap is locally increased due to resistive heating, and the heat generated within the reservoir cap increases the temperature sufficiently to cause the reservoir cap to be electrothermally ablated and ruptured.
- the reservoir cap is formed of an electrically conductive material and the control circuitry comprises an electrical input lead connected to said reservoir cap, an electrical output lead connected to said reservoir cap, wherein the reservoir cap is ruptured by application of an electrical current through the reservoir cap via the input lead and output lead.
- the control circuitry further comprises a source of electric power for applying the electrical current.
- the reservoir opening is closed by a reservoir cap comprising a dielectric or ceramic film layer and the actuation means comprises (i) a electrically conductive (e.g., metal) layer on top of the dielectric or ceramic film layer, and (ii) power source and control circuitry for delivering an electric current through the electrically conductive layer in an amount effective to rupture the dielectric or ceramic film layer, wherein the rupture is due to thermal expansion-induces stress on the dielectric or ceramic film layer.
- the electrically conductive layer and the actuation means can be designed thermally ablate the electrically conductive layer or the electrically conductive layer could remain, in whole or in part, after rupturing the dielectric or ceramic film layer, depending on the particular design for opening/actuation the release of drug from the reservoir.
- the reservoir cap is formed from a material or mixture of materials that degrade, dissolve, or disintegrate over time, or that do not degrade, dissolve, or disintegrate, but are permeable or become permeable to molecules or energy.
- Representative examples of reservoir cap materials include polymeric materials, and non-polymeric materials such as porous forms of metals, semiconductors, and ceramics.
- Passive semiconductor reservoir cap materials include nanoporous or microporous silicon membranes. Characteristics can be different for each reservoir cap to provide different times of release of drug formulation. For example, any combination of polymer, degree of crosslinking, or polymer thickness can be modified to obtain a specific release time or rate.
- a combination of passive and/or active release reservoir cap can be present in a single delivery device.
- the reservoir cap can be removed by electrothermal ablation to expose a passive release system that only begins its passive release after the reservoir cap has been actively removed.
- a given device can include both passive and active release reservoirs.
- release can be controlled from the substrate reservoirs using passive control means, such as a biodegradable matrix material or layering of drug material with non-drug material, without the use of reservoir caps.
- passive control means such as a biodegradable matrix material or layering of drug material with non-drug material
- reservoir caps are provided prior to device use, i.e., prior to application of (adhering) the device to the skin, and then immediately before application to the skin all of these reservoir caps are (manually) removed. For instance, these caps could be part of a protective layer that is removed just prior to adhering the patch to the skin.
- each reservoir includes a single, discrete reservoir cap, covering a single opening that can be opened.
- each reservoir includes two or more openings that can be covered by two or more discrete reservoir caps, where each reservoir cap can, but need not, be independently disintegrated to open the reservoir.
- the reservoir control means can provide intermittent or effectively continuous release of the drug formulation.
- the particular features of the control means depend on the mechanism of reservoir cap activation described herein.
- the control means can include an input source, a microprocessor, a timer, a demultiplexer (or multiplexer), and a power source.
- the power source provides energy to activate the selected reservoir, e.g., to trigger release of the drug formulation from the particular reservoir desired for a given dose. See FIG. 4 .
- the operation of the reservoir opening system can be controlled by an on-board microprocessor.
- the microprocessor can be programmed to initiate the disintegration or permeabilization of the reservoir cap at a pre-selected time or in response to one or more of signals or measured parameters, including receipt of a signal from another device (for example by remote control or wireless methods) or detection of a particular condition using a sensor such as a biosensor.
- a simple state machine is used, as it typically is simpler, smaller, and/or uses less power than a microprocessor.
- the device can also be activated or powered using wireless means, for example, as described in U.S. 2002/0072784 A1 to Sheppard et al., which is incorporated herein by reference.
- the device includes a substrate having a two-dimensional array of reservoirs arranged therein, a drug formulation contained in the reservoirs, anode reservoir caps covering a semi-permeable membrane for each of the reservoirs, cathodes positioned on the substrate near the anodes, and means for actively controlling disintegration of the reservoir caps.
- the means includes a power source and circuitry to control and deliver an electrical potential; the energy drives a reaction between selected anodes and cathodes.
- electrons pass from the anode to the cathode through the external circuit causing the anode material (reservoir cap) to oxidize and dissolve into the surrounding fluids, exposing and releasing the drug formulation.
- the microprocessor directs power to specific electrode pairs through a demultiplexer as directed by an EPROM, remote control, or biosensor.
- the activation energy initiates a thermally driven rupturing or permeabilization process, for example, as described in U.S. Pat. No. 6,527,762.
- the means for controlling release can actively disintegrate or permeabilize a reservoir cap using a resistive heater.
- the resistive heater can cause the reservoir cap to undergo a phase change or fracture, for example, as a result of thermal expansion of the reservoir cap or release system, thereby rupturing the reservoir cap and releasing the drug from the selected reservoir.
- the application of electric current to the resistor can be delivered and controlled using components as described above for use in the electrochemical disintegration embodiment.
- a microprocessor can direct current to select reservoirs at desired intervals.
- control means controls electro-thermal ablation of the reservoir cap.
- the drug delivery device could include a reservoir cap formed of an electrically conductive material; an electrical input lead connected to the reservoir cap; an electrical output lead connected to the reservoir cap; and a control means to deliver an effective amount of electrical current through the reservoir cap, via the input lead and output lead, to locally heat and rupture the reservoir cap, for example to release the drug formulation or expose the sensor located therein.
- the reservoir cap and conductive leads are formed of the same material, where the temperature of the reservoir cap increases locally under applied current because the reservoir cap is suspended in a medium that is less thermally conductive than the substrate.
- the reservoir cap and conductive leads are formed of the same material, and the reservoir cap has a smaller cross-sectional area in the direction of electric current flow, where the increase in current density through the reservoir cap causes an increase in localized heating.
- the reservoir cap alternatively can be formed of a material that is different from the material forming the leads, wherein the material forming the reservoir cap has a different electrical resistivity, thermal diffusivity, thermal conductivity, and/or a lower melting temperature than the material forming the leads.
- control means includes a microprocessor, a timer, a demultiplexer (or multiplexer), and an input source (for example, a memory source, a signal receiver, or a biosensor), and a power source.
- the timer and demultiplexer circuitry can be designed and incorporated directly onto the surface of the microchip during electrode fabrication, or may be incorporated in a separate microchip.
- the microprocessor translates the output from memory sources, signal receivers, or biosensors into an address for the direction of power through the demultiplexer to a specific reservoir on the device.
- a source of input to the microprocessor such as memory sources, signal receivers, or biosensors depends on the microchip device's particular application and whether device operation is preprogrammed, controlled by remote means, or controlled by feedback from its environment (i.e., biofeedback).
- a microprocessor can be used in conjunction with a source of memory such as erasable programmable read only memory (EPROM), a timer, a demultiplexer, and a power source such as a battery or a biofuel cell.
- EPROM erasable programmable read only memory
- a programmed sequence of events including the time a reservoir is to be opened and the location or address of the reservoir is stored into the EPROM by the user.
- the microprocessor When the time for exposure or release has been reached as indicated by the timer, the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer.
- the demultiplexer routes an input, such as an electric potential or current, to the reservoir addressed by the microprocessor.
- the electronics are included on the substrate/chip itself, for example, where the electronics are based on diode or transistor technology known in the art.
- the electronics are separable from the transdermal drug delivery device, such that they are reusable with multiple transdermal drug delivery devices.
- FIG. 2 One example of such a system is shown in FIG. 2 .
- the cost to use a transdermal system like this would be significantly less than a system where the electronics were not separable and only could be used once.
- the securing means can include one or more biocompatible adhesives, straps, or elastic bands.
- the securing means is provided along the periphery of a housing of the device.
- Adhesive securing means can be, or can be readily adapted from, those known in the art for securing transdermal patches, such as those currently used in commercially available transdermal patches. See, e.g., U.S. Pat. No. 6,632,906.
- the adhesive is provided on a thin permeable material, such as a porous polymer layer, or a woven or non-woven fabric layer, which is adjacent the reservoir caps or the transport means.
- the adhesive layer is permeable to the one or more pharmaceutical agents.
- the polymer layer comprises a hydrogel.
- the securing means comprises a pressure sensitive bioadhesive, as known in the art.
- transport means or “means for transporting” refers to any devices or materials for transferring the pharmaceutical agent that has been released from the reservoirs from the opening of the reservoir to the surface of or into the skin of the patient.
- transport mechanism(s) is at least partially dependent on the drug molecule selected for delivery.
- these delivery mechanisms are characterized as follows: (1) passive, (2) chemical penetration enhancers, (3) ultrasonography, (4) iontophoresis, (5) electroosmosis, (6) electroporation, (7) heat, and (8) microneedles.
- passive mechanisms a therapeutic dose is achievable without enhancement because of high potency and desirable physiochemical characteristics, which is typically associated with small lipophilic molecules.
- Chemical penetration enhancers can be added to the drug formulation to increase flux through the skin or mucosal surface.
- Examples include phosphate buffered saline, PEG 200 dilaurate, isopropyl myristate, glycerol trioleate, 50% ethanol/50% phosphate buffered saline, linoleic acid in 1/1 ethanol/phosphate buffered saline.
- ultrasonography low-frequency ultrasound is applied prior to or simultaneously with drug delivery, particularly for low- and high-molecular weight drugs.
- iontophoresis a continuous low current is applied to enhance delivery of a charged molecular species.
- electroosmosis enhancement is by entrainment of bulk liquid by charged ions moving in an electric field, which can be used to deliver neutral and charged species.
- Electroporation utilizes a high voltage pulse to help deliver large (proteins, oligonucleotides) and small molecules. Heat is another mechanism, where controlled exothermic reaction is used to generate heat to drive transport across skin.
- Microneedles which are used to create pathways through the stratum corneum, can take a variety of forms, including an array of titanium microprojections, such as the MACROFLUXTM (Alza Corp.).
- the device can include, or be used with, devices and means for application of acoustic energy (see, e.g., U.S. Patent Application Publication No. 2002/0082527 A1; U.S. Patent Application Publication No. 2002/0045850 A1), sonophoresis/ultrasound (see, e.g., U.S. Pat. No. 6,620,123, U.S. Pat. No. 6,491,657), electroporation, iontophoresis (see, e.g., U.S. Pat. No. 6,629,968, U.S. Pat. No. 6,377,847, U.S. Patent Application Publication No.
- acoustic energy see, e.g., U.S. Patent Application Publication No. 2002/0082527 A1; U.S. Patent Application Publication No. 2002/0045850 A1
- sonophoresis/ultrasound see, e.g., U.S. Pat. No. 6,620,123,
- the transport means comprises a transport medium reservoir disposed between the reservoir caps and the skin.
- the transport medium can include a permeable body through which the one or more pharmaceutical agents can diffuse following their release from the reservoir, or through which an analyte from the patient's skin can diffuse toward sensors disposed in the reservoirs.
- the transport medium can comprise a reservoir containing a liquid, gel, or semi-solid permeation material (also referred to in the art as a rate-limiting membrane).
- suitable permeation materials include various polymers and hydrogels known in the art, which preferably are non-reactive with the drug formulation or skin.
- the transport means includes one or more permeation enhancers, as for example, described in U.S. Pat. No. 6,673,363, which is incorporated herein by reference.
- the means for transporting comprises one or more microneedles.
- microneedles suitable for transdermal drug delivery and analyte sensing are described in U.S. Pat. No. 6,743,211, U.S. Pat. No. 6,661,707, U.S. Pat. No. 6,503,231, and U.S. Pat. No. 6,334,856, all to Prausnitz et al., and in U.S. Pat. No. 6,230,051 and U.S. Pat. No. 6,219,574, both to Cormier et al.
- the device includes positive displacement mechanisms for driving the one or more pharmaceutical agents out of the reservoirs.
- an osmotic pressure generating material or other swellable material drives a piston to force a drug formulation out of the reservoir.
- the device includes features for the positive displacement and/or accelerated release techniques described in U.S. Patent Application Publication No. 2004/0106914 to Coppeta et al.
- the transdermal device includes a patch comprising a secondary reservoir for receiving the drug released from each reservoir in the substrate.
- the secondary reservoir may be a single pool into which the dose is diluted, or the pool space may be divided into individual channels for delivery of each dose with minimal dilution.
- the drug diffuses into and through the secondary reservoir and then out of the patch and into the patient's skin. See FIG. 5 .
- the secondary reservoir is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- the device includes a rigid or flexible housing that contains the substrate, as well as the control means and power source. When the drug enters the secondary reservoir, it may distribute itself homogeneously throughout the secondary reservoir, such that diffusion is substantially uniform across the entire surface area interfacing the skin.
- the secondary reservoir optionally can include a permeable or semi-permeable adhesive layer at this interface.
- FIG. 1 shows device 10 which includes substrate 12 having reservoirs 14 which contain one or more pharmaceutical agents.
- the device 10 further includes fluid reservoir 16 and a permeable adhesive layer 18 for securing the device to the patient's skin.
- the device 10 further includes microprocessor-based or remote control means 20 and battery or other power supply 22 .
- the portion of the device comprising the control mans and power supply is flexible.
- the device includes an optional housing or outer covering 24 .
- fluid reservoir 16 is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- FIG. 6 shows an alternate version of device 10 , wherein the means for transporting further comprises a plurality of microneedles 27 , which may be solid, hollow, or porous.
- a plurality of microneedles 27 which may be solid, hollow, or porous.
- U.S. Pat. No. 6,230,051 to Cormier et al. (Alza Corporation) discloses needle-like protrusions, barbs, or blades that puncture the stratum corneum, and diffusion of drug proceeds along the pathway between the outer surface of the needle and the skin/tissue circumscribing the needle.
- the fluid reservoir is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- the microneedles can be spaced to match the reservoir openings.
- the device electronics optionally can be located in a separate package.
- the device includes a removably attachable electronics portion that comprises the power source and at least a portion of the control circuitry.
- This electronics portion can be re-used many times and can be re-programmed wirelessly, which advantageously could improve cost effectiveness.
- FIGS. 2A-B show device 50 which includes substrate 52 having reservoirs 54 which contain the drug.
- the device 50 further includes fluid reservoir 56 and an adhesive layer 66 for securing the device to the patient's skin.
- the control means for selective releasing the drug includes an electronics interface portion 58 , and removable power and electronics portion 60 .
- the removable power and electronics portion 60 and the electronics interface portion 58 are can be selectively attached together by matingly engaging male connector posts 62 with female receptacles 64 .
- the device is sealed or packaged in a protective material 68 .
- the protective material can be a polymeric coating or laminate composite structure.
- fluid reservoir 56 is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- FIG. 3 shows device 70 (shown only in part) which comprises body portion 72 , which includes a first substrate portion 78 and a second substrate portion 76 .
- Reservoirs 74 are defined in the body portion. (Two are located in the body portion in this illustration, but only one can be seen from the cut-away of part of the first substrate portion.)
- the release opening of the reservoirs are covered by reservoir caps 80 a and 80 b.
- Metal conductors 82 a and 82 b are electrically connected to the reservoir caps, for delivering electric current to the reservoir caps.
- Dielectric layer 85 is provided on the outer surface of the first substrate portion and is underneath the conductors.
- the device can be used to delivery a wide variety of drugs or drug combinations to a patient in need thereof.
- the device can be tailored to delivery the drug or drugs over an extended period of time, with a range of controlled release profiles, for example, to provide a relatively constant or a varied plasma drug levels.
- the device may be removed periodically, provided it does not undesirably interrupt delivery of the drug.
- the drug formulation and device may also be tailored for systemic (bioavailability goal 100%) or topical (bioavailability goal 0%) delivery.
- the medical device is used for transdermal delivery of parathyroid hormone (PTH).
- PTH parathyroid hormone
- PTH is released from the reservoirs in a manner to intermittently deliver a pharmaceutically effective amount of the PTH through the skin for systemic administration.
- the delivery optionally can be facilitated by one or more transport acceleration means as described above.
- kits for treating breakthrough pain in cancer patients.
- the devices can be used to deliver drugs for joint pain, anti-emetic applications, migraine treatments, fertility treatments, and Parkinson's medications.
- the device is used in sensing applications.
- the micro-reservoirs could contain sensors for measuring an analyte that can be drawn from the skin.
- the device could operate not remove fluid but, rather, to place small quantities of solution containing low concentrations of Small Molecule Metabolite Reporters (SMMRs) into the skin for direct reading of the SMMR fluorescence spectral characteristics as an indication of both epidermal skin and blood glucose levels, as known in the art.
- SMMRs Small Molecule Metabolite Reporters
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
Abstract
Devices and methods are provided for transdermal diagnostic sensing, alone or in combination with transdermal drug delivery. The device includes a substrate having a plurality of discrete reservoirs, each reservoir having at least one opening; contents disposed in the reservoirs, the contents of each reservoir including a diagnostic agent or a sensor for measuring an analyte; at least one discrete reservoir cap which cover said at least one opening; control means for disintegrating or permeabilizing the reservoir cap; means for transporting an analyte from the skin to said sensors and/or for transporting said diagnostic agent to the skin following release of said diagnostic agents from said reservoir; and means for securing the device to the skin of a patient.
Description
- This is a divisional of U.S. application Ser. No. 11/194,157, filed Aug. 1, 2005, which claims the benefit of U.S. Provisional Application No. 60/592,537, filed Jul. 30, 2004. The applications are incorporated herein by reference.
- This invention is generally in the field of devices and methods for the transdermal drug delivery and analyte sensing.
- Transdermal drug delivery systems generally rely on diffusion of drug across the skin. In a typical conventional technology, the transdermal drug delivery system is in the form of a multi-layered patch that includes a backing or cover layer, a drug matrix/reservoir, a diffusion control membrane, and an adhesive layer for attaching the system to the surface of the skin. Examples of drugs delivered with such systems include scopolamine (Trasderm-Scop™), nicotine, nitroglycerin (Nitro-Dur™), estradiol (Estraderm™), and testosterone. However, transdermal patches generally are unsuitable for delivery of macromolecules. Others have sought to improve transdermal delivery of drug molecules, particularly where the size and hydrophilicity of the drug molecules significantly hinders diffusion through the stratum corneum, over that obtained with passive diffusion alone, by including with the transdermal drug delivery systems an active mechanism, such as iontophoresis, electroporation, ultrasound, or heat, or by disrupting the stratum corneum with microneedles or the like.
- In transdermal and other drug delivery systems, it is generally desirable to store and protect the drug formulation until the time it is to be delivered to a patient, because exposure to environmental components (e.g., oxygen, humidity) may damage or prematurely degrade the pharmaceutical agent. However, in various conventional transdermal drug delivery systems which contain several days worth of doses of the drug, the entire drug formulation is contained in a single reservoir, such that is it not possible to protect or isolate individual doses. It would be desirable to be able to do so, particularly for relatively fragile pharmaceutical agent molecules.
- In addition, with a conventional patch-type drug delivery system, it generally is not possible to change or fine-tune the rate of administration of drug once the patch is applied to the patient. It would be desirable to provide new and improved methods and devices for the controlled delivery of one or more drugs to a patient by transdermal administration. For example, it would be advantageous to be able to store and transdermally administer multiple discrete doses of a drug formulation, using a device which the physician can easily vary or fine tune the time and rate of drug administration.
- Devices and methods have been developed for transdermal administration of one or more pharmaceutical agents to a patient in need thereof. In one aspect, the device includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps that prevent the pharmaceutical agent from passing out from the reservoirs, control means for actuating release of the pharmaceutical agent from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, means for securing the device to the skin of the patient, and means for transporting to the skin the one or more pharmaceutical agents following release from the one or more of the reservoir. In one embodiment, the device includes a housing which contains the substrate, reservoirs, control means, and a power source. In one embodiment, the device further includes a removably attachable electronics portion which comprises the power source and at least a portion of the control means.
- In one embodiment, the reservoir cap is formed of an electrically conductive material and the control means comprises an electrical input lead connected to said reservoir cap, an electrical output lead connected to said reservoir cap, wherein the reservoir cap is disintegrated by application of an electrical current through the reservoir cap via the input lead and output lead. The device may further include a source of electric power, such as a battery or capacitor, for applying the electrical current.
- In one embodiment, the reservoirs are microreservoirs. In one embodiment, the reservoir cap comprises a metal film.
- In one embodiment, the means for securing the device comprises a pressure sensitive adhesive. In one embodiment, the means for securing comprises an adhesive layer that is permeable to the pharmaceutical agent or analyte.
- In one embodiment, the means for transporting includes a transport medium disposed between the reservoir caps and the skin. For example, the transport medium can include a permeable body through which the pharmaceutical agent released from the reservoirs can diffuse. In one embodiment, the transport medium comprises a reservoir containing a liquid, gel, or semi-solid permeation material. In another embodiment, the means for transporting comprises a plurality of microneedles. In still another embodiment, the means for transporting comprises one or more chemical penetration enhancers. In various embodiments, the means for transporting comprises means for effecting iontophoresis, electroosmosis, or electroporation. In one embodiment, the means for transporting comprises an ultrasound generator. In a further embodiment, the means for transporting comprises a heating element. In one embodiment, the means for transporting comprises a flexible or rigid member having media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution.
- In various specific embodiments, the one or more pharmaceutical agents include a drug selected from among androgen, estrogen, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti-depressants, antibiotics, anti-cancer agents, local anesthetics, antiemetics, anti-infectants, contraceptives, anti-diabetic agents, steroids, anti-allergy agents, anti-migraine agents, agents for smoking cessation, anti-obesity agents, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progestrone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, and combinations thereof.
- In another aspect, a medical device is provided for transdermal administration of one or more pharmaceutical agents to a patient in need thereof, which includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps which prevent the one or more pharmaceutical agents from passing out from the reservoirs, control means for actuating release of the one or more pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, an adhesive or strap material for securing the device to the skin of the patient, and a body defining a transport medium reservoir disposed between the reservoir caps and the skin of the patient, the body and reservoir facilitating transport of the pharmaceutical agent to the skin following its release from one or more of the reservoir. In one embodiment, the transport medium reservoir contains a liquid, gel, or semi-solid permeation material. In one embodiment, the transport medium reservoir comprises a single pool of a biocompatible transport fluid into which the pharmaceutical agent is diluted prior to delivery to the skin. In another embodiment, the transport medium reservoir comprises individual channels for delivery of the pharmaceutical agent with no or minimal dilution prior to delivery to the skin.
- In another aspect, a device is provided for sensing an analyte in a human or other animal. In one embodiment, the device includes a substrate; a plurality of discrete reservoirs in the substrate, the reservoirs having at least one opening; one or more sensors or diagnostic agents stored in the reservoirs; discrete reservoir caps which cover said at least one opening; control means for disintegrating or permeabilizing the reservoir caps; means for securing the device to the skin of the patient; and means for transporting an analyte from the skin to the one or more sensors or for transporting the one or more diagnostic agents to the skin following release of said diagnostic agents from the one or more of the reservoir.
-
FIG. 1 is a cross-sectional view of one embodiment of the medical device for transdermal drug delivery or analyte sensing described herein. -
FIGS. 2A and 2B are a perspective view (FIG. 2A ) and a cross-sectional view (FIG. 2B ) of another embodiment of the medical device for transdermal drug delivery or analyte sensing described herein. -
FIG. 3 is a perspective, cross-sectional view of one embodiment of the reservoir and body portion of the drug delivery or sensing device described herein. -
FIG. 4 is a schematic of the operation of one embodiment of the control means for the medical device for transdermal drug delivery or analyte sensing described herein. -
FIG. 5 is a cross-sectional view of one portion of one embodiment of the device shown inFIG. 1 , showing one reservoir pre-actuation and one reservoir post-actuation. -
FIG. 6 is a cross-sectional view of one embodiment of the medical device for transdermal drug delivery or analyte sensing that includes microneedles. - Medical devices have been developed for the transdermal administration of one or more pharmaceutical agents to patient in need thereof, or for analyte sensing/diagnostics. In a preferred embodiment, the devices isolate each dose or portions of a dose of the pharmaceutical agent within multiple individual (discrete) reservoirs, which typically are arrayed in/across a body portion of the device. Advantageously, the isolated doses or partial doses are protected from environmental components that may damage or prematurely degrade the pharmaceutical agent or other reservoir contents, until the desired time for release or exposure of the pharmaceutical agent or other reservoir contents.
- As used herein, the terms “comprise,” “comprising,” “include,” and “including” are intended to be open, non-limiting terms, unless the contrary is expressly indicated.
- In one aspect, the device comprises a substrate; a plurality of discrete reservoirs in the substrate; one or more pharmaceutical agents stored in the reservoirs; discrete reservoir caps that prevent the one or more pharmaceutical agents from passing out from the reservoirs; control means for actuating release of the pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps; means for securing the device to the skin of the patient; and means for transporting the pharmaceutical agent to the skin following release from one or more of the reservoirs.
- In another aspect, the device is used to deliver a diagnostic agent into the skin. For instance, the agent could be a small molecule metabolite reporter, used in glucose detecting.
- In still another aspect, the device is not used to deliver something but to contain a plurality of sensors for selective exposure. For example, the device could be adapted to sense an analyte withdrawn, either by passive or active mechanisms, from or through the skin.
- The device comprises a substrate, i.e., a body portion, that includes the plurality of discrete reservoirs, e.g., in the form of a two-dimensional array of selectively spaced reservoirs—located in discrete positions—across at least one surface of the body portion. A reservoir is a well, a recess, a hole or a cavity, located in a solid structure and suitable for containing a quantity of another material and/or a secondary device.
- In various embodiments, the body portion comprises silicon, a metal, a ceramic, a polymer, or a combination thereof. Examples of suitable substrate materials include metals, ceramics, semiconductors, glasses, and degradable and non-degradable polymers. In one embodiment, each reservoir is formed of hermetic materials (e.g., metals, silicon, glasses, ceramics) and is hermetically sealed by at least one reservoir cap. In one case, if the reservoir has a second opening, distal the reservoir cap-sealed opening, then a hermetic seal can be formed at that distal opening as well, in order for the reservoir contents to be hermetically isolated within the reservoir. Alternatively, where the reservoir has two opposed openings, each can be covered by a reservoir cap which can be opened for release or exposure of the reservoir contents. In still another case, a reservoir can have two or more separate openings on the same side of the reservoir, which can be covered by one or two or more discrete reservoir caps. The reservoirs can be in essentially any shape, and typically are shaped to facilitate reservoir manufacture and loading of contents, as well as packing of reservoirs into the substrate.
- The substrate can have a variety of shapes, or shaped surfaces. It can, for example, have a release side (i.e., an area having reservoir caps) that is planar or curved. The substrate may, for example, be in a shape selected from circular, square, or ovoid disks. In one embodiment, the release side can be shaped to conform to a curved tissue surface.
- The device body can be flexible or rigid. In one embodiment, the device flexibly conforms to a tissue surface as taught in U.S. Patent Application Publication No. 2002/0099359 to Santini et al., which is incorporated herein by reference.
- The substrate may consist of only one material, or may be a composite or multi-laminate structure, that is, composed of several layers of the same or different substrate materials bonded or fused together. In one embodiment, the substrate comprises layers of silicon and Pyrex bonded together. In another embodiment, the substrate comprises multiple silicon wafers bonded together. In yet another embodiment, the substrate comprises a low-temperature co-fired ceramic (LTCC). In one embodiment, the body portion is the substrate of a microchip device. In one example, this substrate is formed of silicon.
- In one embodiment, the substrate is formed from one or more polymers, copolymers, or blends thereof. For some transdermal applications, the reservoirs need not be defined/enclosed by hermetic materials, particularly where the time the reservoir contents are isolated is relatively short, for example, when the transdermal device is used only for a period of a few days (e.g., less than 2 days, less than 3 days). In such cases, polymeric substrates may be preferred, particularly because they can be less costly to manufacture than some silicon or ceramic substrate devices. In addition, the polymeric substrate can be easily made to conform to a particular skin surface area of the human or animal body.
- In a preferred embodiment, the reservoirs are microreservoirs. As used herein, the term “microreservoir” refers to a discrete hole or concave-shaped space in a solid structure suitable for releasably containing a material. The structure is of a size and shape suitable for filling with a microquantity of the material, which comprises a drug. In one embodiment, the microreservoir has a volume equal to or less than 500 μL (e.g., less than 250 μL, less than 100 μL, less than 50 μL, less than 25 μL, less than 10 μL, etc.) and greater than about 1 nL (e.g., greater than 5 nL, greater than 10 nL, greater than about 25 nL, greater than about 50 nL, greater than about 1 μL, etc.). The shape and dimensions of the microreservoir can be selected to maximize or minimize contact area between the drug material and the surrounding surface of the microreservoir. As used herein, the term “microquantity” refers to small volumes between 1 nL and 500 μL. In one embodiment, the microquantity is between 1 nL and 1 μL. In another embodiment, the microquantity is between 10 nL and 500 nL.
- Microreservoirs can be fabricated in a structural body portion using fabrication techniques known in the art. Representative fabrication techniques include MEMS fabrication processes or other micromachining processes, various drilling techniques (e.g., laser, mechanical, and ultrasonic drilling, electrical discharge machining (EDM)), and build-up techniques, such as LTCC (low temperature co-fired ceramics), punch- or embossing-type processes, thin film or tape processes. The surface of the microreservoir optionally can be treated or coated to alter one or more properties of the surface. Examples of such properties include hydrophilicity/hydrophobicity, wetting properties (surface energies, contact angles, etc.), surface roughness, electrical charge, release characteristics, biocompatibility, and the like. The coating material also can be selected to affect biostability or tissue interactions with the device or with the reservoir contents. Other fabrication processes, particularly ones useful with polymeric substrates, can be used, including injection molding, thermal compression molding, extrusion, embossing, solvent casting, and other polymer forming techniques known in the art. See also U.S. Patent Application Publication No. 2002/0107470 A1 to Richards, et al., which is incorporated herein by reference.
- In other embodiments, the reservoirs are larger than microreservoirs and can contain a quantity of drug formulation larger than a microquantity. For example, the volume of each reservoir can be greater than 10 μL (e.g., at least 20 μL, at least 50 μL, at least 100 μL, at least 250 μL, etc.) and less than 10 mL (e.g., less than 5 mL, less than 1000 μL, less than 500 μL, less than 300 μL, etc.). These may be referred to as macro-reservoirs and macro-quantities, respectively. Unless explicitly indicated to be limited to either micro- or macro-scale volumes/quantities, the term “reservoir” is intended to include both.
- Total substrate thickness and reservoir volume can be increased by bonding or attaching wafers or layers of substrate materials together. The device thickness may affect the volume of each reservoir and/or may affect the maximum number of reservoirs that can be incorporated onto a substrate. The size and number of substrates and reservoirs can be selected to accommodate the quantity and volume of reservoir contents needed for a particular application, manufacturing limitations, and/or total device size limitations suitable for reasonably comfortable attachment to a patient's skin.
- Different device thicknesses may be chosen, depending for example of the type of application. For example, in sensing/diagnostic applications, the thickness may impact analyte transport and thus sensor response. Accordingly, it may be useful to provide a relatively thin substrate for certain sensing devices. As another example, in drug delivery applications, thicker substrates may be desired in order to increase reservoir depth and volume to contain more drug formulation, enabling increased dosage loading.
- The substrate has at least two, or preferably many, discrete reservoirs. In various embodiments, tens, hundreds, or thousands of reservoirs are arrayed across the substrate. For instance, the device could include between 50 and 250 reservoirs, where each reservoir contains a single dose of a drug for release, which for example could be released hourly or daily over a period of several days. Unlike a typical conventional transdermal device, the present multi-reservoir devices can readily store and delivery different drug formulations from a single device. For example, different reservoirs could contain different drugs, or different reservoirs could contain different dosages or concentrations of the same drug.
- In a preferred embodiment, the device comprises a microchip chemical delivery device, as taught in U.S. Pat. No. 5,7979,898, which is incorporated herein by reference. In other embodiments, the device could include polymeric chips or devices, as well other devices containing arrays of reservoirs, composed of non-silicon based materials that might not be referred to as “microchips.”
- Essentially any pharmaceutical agent, i.e., therapeutic or prophylactic agent (e.g., an active pharmaceutical ingredient or API), suitable for transdermal administration can be used with the device described herein. The present devices would be particularly useful for the storage and delivery of drugs that currently are not suitable for use with conventional transdermal systems due to instability issues associated with the drug. For example, a drug or drug formulation that is easily degradable could be protected until needed using the multiple reservoirs, each of which can be hermetically sealed until ruptured when needed to release the drug contained therein. In this way, only the quantity of the drug needed at a particular time is exposed; the remaining drug remains stored and protected. The device can deliver a single pharmaceutical agent or a combination of pharmaceutical agents, which can be stored together in the same reservoir or stored in separate reservoirs. Depending on the application, the device and formulation may be tailored to deliver the active ingredient locally or systemically.
- The pharmaceutical agent (also referred to herein as a drug) can be provided in the reservoirs in a solid, liquid, semi-solid, solution, or suspension, or emulsion formulation. It can be in a pure form or combined with one or more excipient materials. As used herein, “pure form” of the drug includes the API, residual moisture, and any chemical species combined with the API in a specific molar ratio that is isolated with the API during preparation of the API (for instance, a counter-ion) and which has not been added as an excipient.
- In one embodiment, the drug is formulated in a matrix form, comprising a matrix material in which the drug is contained or dispersed. The matrix material further controls release of the drug by controlling dissolution and/or diffusion of the drug from the reservoir, and may enhance stability of the drug molecule while stored in the reservoir.
- In one embodiment, the drug is formulated with an excipient material that is useful for accelerating release, e.g., a water-swellable material that can aid in pushing the drug out of the reservoir and through any tissue capsule over the reservoir. Examples include hydrogels and osmotic pressure generating agents known in the art.
- In another embodiment, the drug is formulated with a penetration enhancer(s). The penetration enhancer(s) further controls release of the drug by facilitating transport of the drug across the skin into the local administration site or systemic delivery.
- Pharmaceutical Agent
- The drug can comprise small molecules, large (i.e., macro-) molecules, or a combination thereof. In one embodiment, the large molecule drug is a protein or a peptide. In various other embodiments, the drug can be selected from amino acids, vaccines, antiviral agents, gene delivery vectors, interleukin inhibitors, immunomodulators, neurotropic factors, neuroprotective agents, antineoplastic agents, chemotherapeutic agents, polysaccharides, anti-coagulants (e.g., LMWH, pentasaccharides), antibiotics (e.g., immunosuppressants), analgesic agents, and vitamins.
- In one embodiment, the drug is a protein. Examples of suitable types of proteins include glycoproteins, enzymes (e.g., proteolytic enzymes), hormones or other analogs (e.g., LHRH, steroids, corticosteroids, growth factors), antibodies (e.g., anti-VEGF antibodies, tumor necrosis factor inhibitors), cytokines (e.g., α-, β-, or γ-interferons), interleukins (e.g., IL-2, IL-10), and diabetes/obesity-related therapeutics (e.g., insulin, exenatide, PYY, GLP-1 and its analogs). In one embodiment, the drug is a gonadotropin-releasing (LHRH) hormone analog, such as leuprolide. In another exemplary embodiment, the drug comprises parathyroid hormone, such as a human parathyroid hormone or its analogs, e.g., hPTH(1-84) or hPTH(1-34). In a further embodiment, the drug is selected from nucleosides, nucleotides, and analogs and conjugates thereof. In yet another embodiment, the drug comprises a peptide with natriuretic activity, such as atrial natriuretic peptide (ANP), B-type (or brain) natriuretic peptide (BNP), C-type natriuretic peptide (CNP), or dendroaspis natriuretic peptide (DNP). In still another embodiment, the drug is selected from diuretics, vasodilators, inotropic agents, anti-arrhythmic agents, Ca+ channel blocking agents, anti-adrenergics/sympatholytics, and renin angiotensin system antagonists. In one embodiment, the drug is a VEGF inhibitor, VEGF antibody, VEGF antibody fragment, or another anti-angiogenic agent. Examples include an aptamer, such as MACUGEN™ (Pfizer/Eyetech) (pegaptanib sodium)) or LUCENTIS™ (Genetech/Novartis) (rhuFab VEGF, or ranibizumab), which could be used in the prevention of choroidal neovascularization. In yet a further embodiment, the drug is a prostaglandin, a prostacyclin, or another drug effective in the treatment of peripheral vascular disease.
- In one embodiment, the device delivers one or more drugs known in the art for use in pain management. Examples include lidocaine and fentanyl. In a further embodiment, the drug is an anti-inflammatory, such as dexamethasone.
- In another embodiment, the drug is an anti-emetic, such as a 5HT-5 antagonist. In yet another embodiment, the drug is a NSAID, such as ketaprofen. In another embodiment, the drug is an anti-anxiety drug, such as benzodiazepines. In still another embodiment, the drug is a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor). In a further embodiment, the drug is an anticoagulant, such as warfarin, heparin, LMWH, oligo-asaccharides such as idraparinux and fondaparinux, and ximelagatran. In still another embodiment, the drug is an angiogenic agent, such as VEGF. In one embodiment, a device includes both angiogenic agents and anti-inflammatory agents. In various embodiments, the drug is a bone morphogenic protein, a growth factor, or a growth or differentiation factor.
- The reservoirs in one device can include a single drug or a combination of two or more drugs, and can further include one or more pharmaceutically acceptable carriers. Two or more can be stored together and released from the same one or more reservoirs or they can each be stored in and released from different reservoirs.
- The device is useful to delivery a variety of drugs, either passively or with the aid of some acceleration means. For example, oligonucleotide drugs may be delivered with the aid of iontophoresis or electroporation.
- Drugs that may be delivered using the devices and methods described herein include those listed in Table 1 below.
-
TABLE 1 Transdermal Drug Delivery Compounds Current Delivery Existing Drug Name Mechanism(s) Notes Clonidine Passive Marketed Estradiol Passive Marketed Fentanyl Passive, Iontophoresis Marketed Nicotine Passive Marketed Nitroglycerin Passive Marketed Scopolamine Passive Marketed Testosterone Passive Marketed Lidocaine Iontophoresis Marketed Epinephrine Iontophoresis Research Corticosteroids Iontophoresis Research Pilocarpine Iontophoresis Marketed; cystic fibrosis diagnosis Nafarelin Iontophoresis Research; Pharm Res 13, 798 Leuprolide Iontophoresis Research; J. Control. Release 31, 41 Vasopressin Iontophoresis Research Salmon calcitonin Iontophoresis Research; Pharm. Res. 14, 63 Insulin Iontophoresis Research; Electrically Assisted Transdermal & Topical Drug Delivery 1998 LHRH Iontophoresis Research; J. Phar. Sci. 87, 462 Parathyroid hormone Iontophoresis Research Desmopressin Iontophoresis Research; Biol. Pharm. Bull. 21, 268 δ-sleep-inducing peptide Iontophoresis Research; Drug. Dev. Ind. Pharm. 24, 431 - Excipients and Matrix Materials
- The drug can be dispersed in a matrix material, to further control the rate of release of drug. This matrix material can be a “release system,” as described in U.S. Pat. No. 5,797,898, the degradation, dissolution, or diffusion properties of which can provide a method for controlling the release rate of the chemical molecules.
- The release system may provide a temporally modulated release profile (e.g., pulsatile release) when time variation in plasma levels is desired or a more continuous or consistent release profile when a constant plasma level as needed to enhance a therapeutic effect, for example. Pulsatile release can be achieved from an individual reservoir, from a plurality of reservoirs, or a combination thereof. For example, where each reservoir provides only a single pulse, multiple pulses (i.e., pulsatile release) are achieved by temporally staggering the single pulse release from each of several reservoirs. Alternatively, multiple pulses can be achieved from a single reservoir by incorporating several layers of a release system and other materials into a single reservoir. Continuous release can be achieved by incorporating a release system that degrades, dissolves, or allows diffusion of molecules through it over an extended period. In addition, continuous release can be approximated by releasing several pulses of molecules in rapid succession (“digital” release). The active release systems described herein can be used alone or on combination with passive release systems, for example, as described in U.S. Pat. No. 5,797,898. For example, the reservoir cap can be removed by active means to expose a passive release system, or a given substrate can include both passive and active release reservoirs.
- In one embodiment, the drug formulation within a reservoir comprises layers of drug and non-drug material. After the active release mechanism has exposed the reservoir contents, the multiple layers provide multiple pulses of drug release due to intervening layers of non-drug. In another variation, the same layering system could be used in device operating by passive release.
- The pharmaceutical agent can be formulated with one or more pharmaceutically acceptable excipients. Representative examples include bulking agents, wetting agents, stabilizers, crystal growth inhibitors, antioxidants, antimicrobials, preservatives, buffering agents (e.g., acids, bases), surfactants, desiccants, dispersants, osmotic agents, binders (e.g., starch, gelatin), disintegrants (e.g., celluloses), glidants (e.g., talc), diluents (e.g., lactose, dicalcium phosphate), color agents, lubricants (e.g., magnesium stearate, hydrogenated vegetable oils) and combinations thereof. In some embodiments, the excipient is a wax or a polymer. In one embodiment, the polymer comprises polyethylene glycol (PEG), e.g., typically one having a molecular weight between about 100 and 10,000 Daltons (e.g., PEG 200, PEG 1450). In another embodiment, the polymer comprises poly lactic acid (PLA), poly glycolic acid (PGA), copolymers thereof (PLGA), or ethyl-vinyl acetate (EVA) polymers. In yet another embodiment, the excipient material comprises a pharmaceutically acceptable oil (e.g., sesame oil).
- In one embodiment, the excipient material includes a saturated drug solution. That is, the excipient material comprises a liquid solution formed of the drug dissolved in a solvent for the drug. The solution is saturated so that the solvent does not dissolve the solid matrix form of the drug. The saturated solution acts as a non-solvent excipient material, substantially filling pores and voids in the solid matrix.
- In another embodiment, the excipient material comprises a pharmaceutically-acceptable perhalohydrocarbon or unsubstituted saturated hydrocarbon. See, for example, U.S. Pat. No. 6,264,990 to Knepp et al., which describes anhydrous, aprotic, hydrophobic, non-polar liquids, such as biocompatible perhalohydrocarbons or unsubstituted saturated hydrocarbons, such as perfluorodecalin, perflurobutylamine, perfluorotripropylamine, perfluoro-N-methyldecahydroquindine, perfluoro-octohydro quinolidine, perfluoro-N-cyclohexylpyrilidine, perfluoro-N,N-dimethylcyclohexyl methylamine, perfluoro-dimethyl-adamantane, perfluorotri-methylbicyclo (3.3.1) nonane, bis(perfluorohexyl) ethene, bis(perfluorobutyl) ethene, perfluoro-1-butyl-2-hexyl ethene, tetradecane, methoxyflurane and mineral oil.).
- In one embodiment, the pharmaceutically acceptable excipient material comprises dimethyl sulfoxide (DMSO), glycerol, or ethanol.
- In certain embodiments, the excipient material can be one that would not ordinarily be considered as ingredient in a dosage form. Where the implantable drug delivery device comprises one or more discrete reservoirs of small volume, e.g., microreservoirs, then it may be desirable to use organic solvents that are not possible to use in large amounts, for example due to toxicity concerns. In various embodiments, the solvents listed in Table 2 can be used as the excipient material if the device reservoir volumes are small enough to ensure that the daily exposure to the excipient cannot exceed predetermined limits, for example described in ICH Guideline Q3C: Impurities: Residual Solvents.
-
TABLE 2 Excipient Materials and Exposure Limits Excipient Daily limit (mg) Benzene 0.02 Carbon tetrachloride 0.04 1,2-Dichloroethane 0.05 1,1-Dichloroethene 0.08 1,1,1-Trichloroethane 15 Acetonitrile 4.1 Chlorobenzene 3.6 Chloroform 0.6 Cyclohexane 38.8 1,2-Dichloroethene 18.7 Dichloromethane 6.0 1,2-Dimethoxyethane 1.0 N,N-Dimethylacetamide 10.9 N,N-Dimethylformamide 8.8 1,4-Dioxane 3.8 2-Ethoxyethanol 1.6 Ethyleneglycol 6.2 Formamide 2.2 Hexane 2.9 Methanol 30.0 2-Methoxyethanol 0.5 Methylbutyl ketone 0.5 Methylcyclohexane 11.8 N-Methylpyrrolidone 5.3 Nitromethane 0.5 Pyridine 2.0 Sulfolane 1.6 Tetrahydrofuran 7.2 Tetralin 1.0 Toluene 8.9 1,1,2-Trichloroethene 0.8 Xylene 21.7 Acetic acid 50 Acetone 50 Anisole 50 1- Butanol 50 2- Butanol 50 Butyl acetate 50 tert- Butylmethyl ether 50 Cumene 50 Dimethyl sulfoxide 50 Ethanol 50 Ethyl acetate 50 Ethyl ether 50 Ethyl formate 50 Formic acid 50 Heptane 50 Isobutyl acetate 50 Isopropyl acetate 50 Methyl acetate 50 3-Methyl-1- butanol 50 Methylethyl ketone 50 Methylisobutyl ketone 50 2-Methyl-1- propanol 50 Pentane 50 1- Pentanol 50 1- Propanol 50 2- Propanol 50 Propyl acetate 50 - The device includes structural components for controlling the time at which release of the pharmaceutical agent from the reservoir is initiated. These components include reservoir caps and reservoir control means. In one embodiment, the control means includes control circuitry, which includes the hardware, electrical components, and software needed to control and deliver electric energy from a power source to selected reservoir(s) for actuation, e.g., reservoir opening.
- Reservoir Caps
- As used herein, the term “reservoir cap” includes a membrane or other structure suitable for separating the contents of a reservoir from the environment outside of the reservoir. It generally is self-supporting across the reservoir opening, although caps having additional structures to provide mechanical support to the cap can be fabricated. See, e.g., U.S. Patent Application Publication Nos. 2002/0183721 A1, which is incorporated herein by reference. Selectively removing the reservoir cap or making it permeable will then “expose” the contents of the reservoir to the environment (or selected components thereof) surrounding the reservoir. In preferred embodiments, the reservoir cap is selectively disintegrated. As used herein, the term “disintegrate” includes degrading, dissolving, rupturing, fracturing or some other form of mechanical failure, as well as a loss of structural integrity due to a chemical reaction (e.g., electrochemical degradation) or phase change (e.g., melting) in response to a change in temperature, unless a specific one of these mechanisms is indicated. In one specific embodiment, the “disintegration” is by an electrochemical activation technique, such as described in U.S. Pat. No. 5,797,898. In another specific embodiment, the “disintegration” is by an electro-thermal ablation technique, as described in U.S. Patent Application Publication No. 2004/0121486 A1 to Uhland et al., which is incorporated herein by reference in its entirety.
- In one embodiment, the reservoir cap is a thin metal film and is impermeable to the surrounding environment (e.g., body fluids or another chloride containing solution). In one variation, a particular electric potential is applied to the metal reservoir cap, which is then oxidized and disintegrated by an electrochemical reaction, to release the drug from the reservoir. Examples of suitable reservoir cap materials include gold, silver, copper, and zinc.
- In another variation, the reservoir cap is heated (e.g., using resistive heating) to cause the reservoir cap to melt and be displaced from the reservoir to open it. See U.S. Pat. No. 6,527,762, which is incorporated herein by reference. This latter variation could be used, for example, with reservoir caps formed of a metal or a non-metal material, e.g., a polymer. In yet another variation, the reservoir cap is formed of a polymer or other material that undergoes a temperature-dependent change in permeability such that upon heating to a pre-selected temperature, the reservoir is rendered permeable to the drug and bodily fluids to permit the drug to be released from the reservoir through the reservoir cap.
- In still another embodiment, the reservoir cap is formed of a conductive material, such as a metal film, through which an electrical current can be passed to electrothermally ablate it, as described in U.S. Patent Application Publication No. 2004/0121486 A1 to Uhland et al. Representative examples of suitable reservoir cap materials include gold, copper, aluminum, silver, platinum, titanium, palladium, various alloys (e.g., Au—Si, Au—Ge, Pt—Ir, Ni—Ti, Pt—Si, SS 304, SS 316), and silicon doped with an impurity to modulate the conductivity/resistivity because one can use the impurity to increase or decrease the conductivity or resistivity of the silicon, as known in the art. In one embodiment, the reservoir cap is in the form of a thin metal film. In one embodiment, the reservoir cap is part of a multiple layer structure, for example, the reservoir cap can be made of multiple metal layers, such as a multi-layer/laminate structure of platinum/titanium/platinum. The reservoir cap is operably (i.e., electrically) connected to an electrical input lead and to an electrical output lead, to facilitate flow of an electrical current through the reservoir cap. When an effective amount of an electrical current is applied through the leads and reservoir cap, the temperature of the reservoir cap is locally increased due to resistive heating, and the heat generated within the reservoir cap increases the temperature sufficiently to cause the reservoir cap to be electrothermally ablated and ruptured. In this embodiment, the reservoir cap is formed of an electrically conductive material and the control circuitry comprises an electrical input lead connected to said reservoir cap, an electrical output lead connected to said reservoir cap, wherein the reservoir cap is ruptured by application of an electrical current through the reservoir cap via the input lead and output lead. Preferably, the control circuitry further comprises a source of electric power for applying the electrical current.
- In yet another embodiment, the reservoir opening is closed by a reservoir cap comprising a dielectric or ceramic film layer and the actuation means comprises (i) a electrically conductive (e.g., metal) layer on top of the dielectric or ceramic film layer, and (ii) power source and control circuitry for delivering an electric current through the electrically conductive layer in an amount effective to rupture the dielectric or ceramic film layer, wherein the rupture is due to thermal expansion-induces stress on the dielectric or ceramic film layer. The electrically conductive layer and the actuation means can be designed thermally ablate the electrically conductive layer or the electrically conductive layer could remain, in whole or in part, after rupturing the dielectric or ceramic film layer, depending on the particular design for opening/actuation the release of drug from the reservoir.
- In passive release devices, the reservoir cap is formed from a material or mixture of materials that degrade, dissolve, or disintegrate over time, or that do not degrade, dissolve, or disintegrate, but are permeable or become permeable to molecules or energy. Representative examples of reservoir cap materials include polymeric materials, and non-polymeric materials such as porous forms of metals, semiconductors, and ceramics. Passive semiconductor reservoir cap materials include nanoporous or microporous silicon membranes. Characteristics can be different for each reservoir cap to provide different times of release of drug formulation. For example, any combination of polymer, degree of crosslinking, or polymer thickness can be modified to obtain a specific release time or rate.
- A combination of passive and/or active release reservoir cap can be present in a single delivery device. For example, the reservoir cap can be removed by electrothermal ablation to expose a passive release system that only begins its passive release after the reservoir cap has been actively removed. Alternatively, a given device can include both passive and active release reservoirs.
- In still another embodiment, release can be controlled from the substrate reservoirs using passive control means, such as a biodegradable matrix material or layering of drug material with non-drug material, without the use of reservoir caps. In one variation of this “no cap” approach, reservoir caps are provided prior to device use, i.e., prior to application of (adhering) the device to the skin, and then immediately before application to the skin all of these reservoir caps are (manually) removed. For instance, these caps could be part of a protective layer that is removed just prior to adhering the patch to the skin.
- In one embodiment, each reservoir includes a single, discrete reservoir cap, covering a single opening that can be opened. In another embodiment, each reservoir includes two or more openings that can be covered by two or more discrete reservoir caps, where each reservoir cap can, but need not, be independently disintegrated to open the reservoir. There can be a one-to-one correspondence between the number of reservoir openings and the number of reservoir caps; however, in various embodiments, it is possible that a single discrete reservoir can cover more than one reservoir opening.
- Control Means
- The reservoir control means can provide intermittent or effectively continuous release of the drug formulation. The particular features of the control means depend on the mechanism of reservoir cap activation described herein. For example, the control means can include an input source, a microprocessor, a timer, a demultiplexer (or multiplexer), and a power source. The power source provides energy to activate the selected reservoir, e.g., to trigger release of the drug formulation from the particular reservoir desired for a given dose. See
FIG. 4 . For example, the operation of the reservoir opening system can be controlled by an on-board microprocessor. The microprocessor can be programmed to initiate the disintegration or permeabilization of the reservoir cap at a pre-selected time or in response to one or more of signals or measured parameters, including receipt of a signal from another device (for example by remote control or wireless methods) or detection of a particular condition using a sensor such as a biosensor. In another embodiment, a simple state machine is used, as it typically is simpler, smaller, and/or uses less power than a microprocessor. The device can also be activated or powered using wireless means, for example, as described in U.S. 2002/0072784 A1 to Sheppard et al., which is incorporated herein by reference. - In one embodiment, the device includes a substrate having a two-dimensional array of reservoirs arranged therein, a drug formulation contained in the reservoirs, anode reservoir caps covering a semi-permeable membrane for each of the reservoirs, cathodes positioned on the substrate near the anodes, and means for actively controlling disintegration of the reservoir caps. The means includes a power source and circuitry to control and deliver an electrical potential; the energy drives a reaction between selected anodes and cathodes. Upon application of a potential between the electrodes, electrons pass from the anode to the cathode through the external circuit causing the anode material (reservoir cap) to oxidize and dissolve into the surrounding fluids, exposing and releasing the drug formulation. The microprocessor directs power to specific electrode pairs through a demultiplexer as directed by an EPROM, remote control, or biosensor.
- In another embodiment, the activation energy initiates a thermally driven rupturing or permeabilization process, for example, as described in U.S. Pat. No. 6,527,762. For example, the means for controlling release can actively disintegrate or permeabilize a reservoir cap using a resistive heater. The resistive heater can cause the reservoir cap to undergo a phase change or fracture, for example, as a result of thermal expansion of the reservoir cap or release system, thereby rupturing the reservoir cap and releasing the drug from the selected reservoir. The application of electric current to the resistor can be delivered and controlled using components as described above for use in the electrochemical disintegration embodiment. For example, a microprocessor can direct current to select reservoirs at desired intervals.
- In a preferred embodiment, control means controls electro-thermal ablation of the reservoir cap. For example, the drug delivery device could include a reservoir cap formed of an electrically conductive material; an electrical input lead connected to the reservoir cap; an electrical output lead connected to the reservoir cap; and a control means to deliver an effective amount of electrical current through the reservoir cap, via the input lead and output lead, to locally heat and rupture the reservoir cap, for example to release the drug formulation or expose the sensor located therein. In one embodiment, the reservoir cap and conductive leads are formed of the same material, where the temperature of the reservoir cap increases locally under applied current because the reservoir cap is suspended in a medium that is less thermally conductive than the substrate. Alternatively, the reservoir cap and conductive leads are formed of the same material, and the reservoir cap has a smaller cross-sectional area in the direction of electric current flow, where the increase in current density through the reservoir cap causes an increase in localized heating. The reservoir cap alternatively can be formed of a material that is different from the material forming the leads, wherein the material forming the reservoir cap has a different electrical resistivity, thermal diffusivity, thermal conductivity, and/or a lower melting temperature than the material forming the leads. Various combinations of these embodiments can be employed as described in U.S. Patent Application Publication No. 2004/0121486 A1 to Uhland et al.
- In one embodiment, the control means includes a microprocessor, a timer, a demultiplexer (or multiplexer), and an input source (for example, a memory source, a signal receiver, or a biosensor), and a power source. The timer and demultiplexer circuitry can be designed and incorporated directly onto the surface of the microchip during electrode fabrication, or may be incorporated in a separate microchip. The microprocessor translates the output from memory sources, signal receivers, or biosensors into an address for the direction of power through the demultiplexer to a specific reservoir on the device. Selection of a source of input to the microprocessor such as memory sources, signal receivers, or biosensors depends on the microchip device's particular application and whether device operation is preprogrammed, controlled by remote means, or controlled by feedback from its environment (i.e., biofeedback). For example, a microprocessor can be used in conjunction with a source of memory such as erasable programmable read only memory (EPROM), a timer, a demultiplexer, and a power source such as a battery or a biofuel cell. A programmed sequence of events including the time a reservoir is to be opened and the location or address of the reservoir is stored into the EPROM by the user. When the time for exposure or release has been reached as indicated by the timer, the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer. The demultiplexer routes an input, such as an electric potential or current, to the reservoir addressed by the microprocessor. In another embodiment, the electronics are included on the substrate/chip itself, for example, where the electronics are based on diode or transistor technology known in the art.
- In one preferred embodiment, the electronics are separable from the transdermal drug delivery device, such that they are reusable with multiple transdermal drug delivery devices. One example of such a system is shown in
FIG. 2 . The cost to use a transdermal system like this would be significantly less than a system where the electronics were not separable and only could be used once. - Other methods and multi-reservoir devices for controlled release of drug are described in U.S. Patent Application Publications Nos. 2002/0072784 A1, 2002/0099359 A1, 2002/0187260 A1, 2003/0010808 A1, 2004/0082937 A1, 2004/016914 A1; and U.S. Pat. Nos. 6,808,522, 6,730,072, 6,773,429, 6,123,861, all of which are incorporated by reference herein.
- Essentially any device known in the art for securing objects to the skin of a human or other mammalian animal can be used. For example, the securing means can include one or more biocompatible adhesives, straps, or elastic bands. In one embodiment, the securing means is provided along the periphery of a housing of the device. Adhesive securing means can be, or can be readily adapted from, those known in the art for securing transdermal patches, such as those currently used in commercially available transdermal patches. See, e.g., U.S. Pat. No. 6,632,906.
- In one embodiment, the adhesive is provided on a thin permeable material, such as a porous polymer layer, or a woven or non-woven fabric layer, which is adjacent the reservoir caps or the transport means. In one embodiment, the adhesive layer is permeable to the one or more pharmaceutical agents. In one embodiment, the polymer layer comprises a hydrogel.
- In a preferred embodiment, the securing means comprises a pressure sensitive bioadhesive, as known in the art.
- As used herein, “transport means” or “means for transporting” refers to any devices or materials for transferring the pharmaceutical agent that has been released from the reservoirs from the opening of the reservoir to the surface of or into the skin of the patient.
- The choice of transport mechanism(s) is at least partially dependent on the drug molecule selected for delivery. Generally, these delivery mechanisms are characterized as follows: (1) passive, (2) chemical penetration enhancers, (3) ultrasonography, (4) iontophoresis, (5) electroosmosis, (6) electroporation, (7) heat, and (8) microneedles. For passive mechanisms, a therapeutic dose is achievable without enhancement because of high potency and desirable physiochemical characteristics, which is typically associated with small lipophilic molecules. Chemical penetration enhancers can be added to the drug formulation to increase flux through the skin or mucosal surface. Examples include phosphate buffered saline, PEG 200 dilaurate, isopropyl myristate, glycerol trioleate, 50% ethanol/50% phosphate buffered saline, linoleic acid in 1/1 ethanol/phosphate buffered saline. With ultrasonography, low-frequency ultrasound is applied prior to or simultaneously with drug delivery, particularly for low- and high-molecular weight drugs. With iontophoresis, a continuous low current is applied to enhance delivery of a charged molecular species. With electroosmosis, enhancement is by entrainment of bulk liquid by charged ions moving in an electric field, which can be used to deliver neutral and charged species. Electroporation utilizes a high voltage pulse to help deliver large (proteins, oligonucleotides) and small molecules. Heat is another mechanism, where controlled exothermic reaction is used to generate heat to drive transport across skin. Microneedles, which are used to create pathways through the stratum corneum, can take a variety of forms, including an array of titanium microprojections, such as the MACROFLUX™ (Alza Corp.).
- The device can include, or be used with, devices and means for application of acoustic energy (see, e.g., U.S. Patent Application Publication No. 2002/0082527 A1; U.S. Patent Application Publication No. 2002/0045850 A1), sonophoresis/ultrasound (see, e.g., U.S. Pat. No. 6,620,123, U.S. Pat. No. 6,491,657), electroporation, iontophoresis (see, e.g., U.S. Pat. No. 6,629,968, U.S. Pat. No. 6,377,847, U.S. Patent Application Publication No. 2001/0056255 A1), heat (see, e.g., U.S. Pat. No. 6,756,053, U.S. Pat. No. 6,488,959) or other means known in the art for enhancing transdermal administration of drugs or transdermal diagnostics (e.g., glucose sensing).
- In one embodiment, the transport means comprises a transport medium reservoir disposed between the reservoir caps and the skin. For example, the transport medium can include a permeable body through which the one or more pharmaceutical agents can diffuse following their release from the reservoir, or through which an analyte from the patient's skin can diffuse toward sensors disposed in the reservoirs. The transport medium can comprise a reservoir containing a liquid, gel, or semi-solid permeation material (also referred to in the art as a rate-limiting membrane). Representative examples of suitable permeation materials include various polymers and hydrogels known in the art, which preferably are non-reactive with the drug formulation or skin.
- In one embodiment, the transport means includes one or more permeation enhancers, as for example, described in U.S. Pat. No. 6,673,363, which is incorporated herein by reference.
- In one embodiment, the means for transporting comprises one or more microneedles. Examples of microneedles suitable for transdermal drug delivery and analyte sensing are described in U.S. Pat. No. 6,743,211, U.S. Pat. No. 6,661,707, U.S. Pat. No. 6,503,231, and U.S. Pat. No. 6,334,856, all to Prausnitz et al., and in U.S. Pat. No. 6,230,051 and U.S. Pat. No. 6,219,574, both to Cormier et al.
- In one embodiment, the device includes positive displacement mechanisms for driving the one or more pharmaceutical agents out of the reservoirs. In one embodiment, an osmotic pressure generating material or other swellable material drives a piston to force a drug formulation out of the reservoir. In another embodiment, the device includes features for the positive displacement and/or accelerated release techniques described in U.S. Patent Application Publication No. 2004/0106914 to Coppeta et al.
- In one embodiment, the transdermal device includes a patch comprising a secondary reservoir for receiving the drug released from each reservoir in the substrate. The secondary reservoir may be a single pool into which the dose is diluted, or the pool space may be divided into individual channels for delivery of each dose with minimal dilution. Upon release from the substrate reservoir, the drug diffuses into and through the secondary reservoir and then out of the patch and into the patient's skin. See
FIG. 5 . In an alternative embodiment (not shown) the secondary reservoir is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution. In one embodiment, the device includes a rigid or flexible housing that contains the substrate, as well as the control means and power source. When the drug enters the secondary reservoir, it may distribute itself homogeneously throughout the secondary reservoir, such that diffusion is substantially uniform across the entire surface area interfacing the skin. The secondary reservoir optionally can include a permeable or semi-permeable adhesive layer at this interface. -
FIG. 1 showsdevice 10 which includessubstrate 12 havingreservoirs 14 which contain one or more pharmaceutical agents. Thedevice 10 further includesfluid reservoir 16 and a permeableadhesive layer 18 for securing the device to the patient's skin. Thedevice 10 further includes microprocessor-based or remote control means 20 and battery orother power supply 22. Preferably, the portion of the device comprising the control mans and power supply is flexible. The device includes an optional housing orouter covering 24. In an alternative embodiment (not shown)fluid reservoir 16 is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution. -
FIG. 6 shows an alternate version ofdevice 10, wherein the means for transporting further comprises a plurality ofmicroneedles 27, which may be solid, hollow, or porous. For example, U.S. Pat. No. 6,230,051 to Cormier et al. (Alza Corporation) discloses needle-like protrusions, barbs, or blades that puncture the stratum corneum, and diffusion of drug proceeds along the pathway between the outer surface of the needle and the skin/tissue circumscribing the needle. In an alternative embodiment, the fluid reservoir is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution. That is, the microneedles can be spaced to match the reservoir openings. In use, one can apply the solid microneedles first, then remove them, and then apply the drug delivery patch, or one can use hollow microneedles matched to the spacing of the reservoir openings attached to the patch. - The device electronics optionally can be located in a separate package. In one embodiment, the device includes a removably attachable electronics portion that comprises the power source and at least a portion of the control circuitry. This electronics portion can be re-used many times and can be re-programmed wirelessly, which advantageously could improve cost effectiveness. One embodiment of such a device is illustrated in
FIGS. 2A-B . These Figures showdevice 50 which includessubstrate 52 havingreservoirs 54 which contain the drug. Thedevice 50 further includesfluid reservoir 56 and anadhesive layer 66 for securing the device to the patient's skin. The control means for selective releasing the drug includes anelectronics interface portion 58, and removable power andelectronics portion 60. The removable power andelectronics portion 60 and theelectronics interface portion 58 are can be selectively attached together by matingly engaging male connector posts 62 withfemale receptacles 64. The device is sealed or packaged in aprotective material 68. For example, the protective material can be a polymeric coating or laminate composite structure. In an alternative embodiment (not shown)fluid reservoir 56 is replaced with a layer of substrate that has media-filled holes with spacing corresponding to reservoir membrane openings, which allows release of reservoir contents without dilution. -
FIG. 3 shows device 70 (shown only in part) which comprisesbody portion 72, which includes afirst substrate portion 78 and asecond substrate portion 76.Reservoirs 74 are defined in the body portion. (Two are located in the body portion in this illustration, but only one can be seen from the cut-away of part of the first substrate portion.) The release opening of the reservoirs are covered byreservoir caps Metal conductors Dielectric layer 85 is provided on the outer surface of the first substrate portion and is underneath the conductors. - In preferred embodiments, the device can be used to delivery a wide variety of drugs or drug combinations to a patient in need thereof. The device can be tailored to delivery the drug or drugs over an extended period of time, with a range of controlled release profiles, for example, to provide a relatively constant or a varied plasma drug levels. The device may be removed periodically, provided it does not undesirably interrupt delivery of the drug. The drug formulation and device may also be tailored for systemic (bioavailability goal 100%) or topical (bioavailability goal 0%) delivery.
- In one embodiment, the medical device is used for transdermal delivery of parathyroid hormone (PTH). PTH is released from the reservoirs in a manner to intermittently deliver a pharmaceutically effective amount of the PTH through the skin for systemic administration. The delivery optionally can be facilitated by one or more transport acceleration means as described above.
- Other applications include the delivery of pain medications. Examples include lidocaine, for needle sticks, IV insertion, or other dermatological procedures, or the delivery of more potent pain medications, such as fentanyl, for greater pain relief, such as for treating breakthrough pain in cancer patients. In still other applications, the devices can be used to deliver drugs for joint pain, anti-emetic applications, migraine treatments, fertility treatments, and Parkinson's medications.
- In still other applications, the device is used in sensing applications. For example, the micro-reservoirs could contain sensors for measuring an analyte that can be drawn from the skin. Alternatively, the device could operate not remove fluid but, rather, to place small quantities of solution containing low concentrations of Small Molecule Metabolite Reporters (SMMRs) into the skin for direct reading of the SMMR fluorescence spectral characteristics as an indication of both epidermal skin and blood glucose levels, as known in the art.
- Publications cited herein and the materials for which they are cited are specifically incorporated by reference. Modifications and variations of the methods and devices described herein will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.
Claims (20)
1. A device for sensing an analyte in a human or other animal comprising:
a substrate having a plurality of discrete reservoirs, each reservoir having at least one opening;
contents disposed in the reservoirs, the contents of each reservoir comprising a diagnostic agent or a sensor for measuring an analyte;
at least one discrete reservoir cap which cover said at least one opening;
control means for disintegrating or permeabilizing the reservoir cap;
means for transporting an analyte from the skin to said sensors and/or for transporting said diagnostic agent to the skin following release of said diagnostic agents from said reservoir; and
means for securing the device to the skin of a patient.
2. The device of claim 1 , wherein the reservoir cap is formed of an electrically conductive material and the circuitry comprises an electrical input lead connected to said reservoir cap, an electrical output lead connected to said reservoir cap, wherein the reservoir cap is ruptured by application of an electrical current through the reservoir cap via the input lead and output lead.
3. The device of claim 1 , wherein the reservoir cap comprises a metal film.
4. The device of claim 1 , wherein the means for transporting comprises a transport medium disposed between the reservoir caps and the skin.
5. The device of claim 4 , wherein the transport medium comprises a permeable body through which the one or more diagnostic agents released from the reservoirs can diffuse.
6. The device of claim 4 , wherein the transport medium comprises a reservoir containing a liquid, gel, or semi-solid permeation material.
7. The device of claim 1 , wherein the means for transporting comprises a flexible or rigid member having media-filled holes with spacing corresponding to reservoir membrane openings.
8. The device of claim 6 , wherein the transport medium reservoir comprises a single pool of a biocompatible transport fluid into which the one or more diagnostic agents are diluted prior to delivery to the skin.
9. The device of claim 6 , wherein the transport medium reservoir comprises individual channels for delivery of the one or more diagnostic agents with no or minimal dilution prior to delivery to the skin.
10. The device of claim 1 , further comprising a housing which contains the substrate and control means.
11. The device of claim 1 , comprising a removably attachable electronics portion which comprises a power source and at least a portion of the control means.
12. The device of claim 1 , wherein the means for transporting comprises a plurality of microneedles.
13. The device of claim 1 , wherein the means for transporting comprises one or more chemical penetration enhancers.
14. The device of claim 1 , wherein the means for transporting comprises an ultrasound generator.
15. The device of claim 1 , wherein the means for transporting comprises means for effecting iontophoresis, electroosmosis, or electroporation.
16. The device of claim 1 , wherein the means for transporting comprises a heating element.
17. The device of claim 1 , wherein the reservoirs are microreservoirs.
18. The device of claim 1 , wherein the means for securing comprises a pressure sensitive adhesive, an adhesive layer which is permeable to the one or more diagnostic agents, or a combination thereof.
19. The device of claim 1 , wherein the diagnostic agent comprises a Small Molecule Metabolite Reporter.
20. The device of claim 1 , wherein the sensor can measure the epidermal skin or blood glucose level in a patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/471,973 US20090234214A1 (en) | 2004-07-30 | 2009-05-26 | Multi-reservoir device and method for transdermal sensing |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59253704P | 2004-07-30 | 2004-07-30 | |
US11/194,157 US7537590B2 (en) | 2004-07-30 | 2005-08-01 | Multi-reservoir device for transdermal drug delivery and sensing |
US12/471,973 US20090234214A1 (en) | 2004-07-30 | 2009-05-26 | Multi-reservoir device and method for transdermal sensing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/194,157 Division US7537590B2 (en) | 2004-07-30 | 2005-08-01 | Multi-reservoir device for transdermal drug delivery and sensing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090234214A1 true US20090234214A1 (en) | 2009-09-17 |
Family
ID=35539550
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/194,157 Expired - Fee Related US7537590B2 (en) | 2004-07-30 | 2005-08-01 | Multi-reservoir device for transdermal drug delivery and sensing |
US12/471,973 Abandoned US20090234214A1 (en) | 2004-07-30 | 2009-05-26 | Multi-reservoir device and method for transdermal sensing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/194,157 Expired - Fee Related US7537590B2 (en) | 2004-07-30 | 2005-08-01 | Multi-reservoir device for transdermal drug delivery and sensing |
Country Status (2)
Country | Link |
---|---|
US (2) | US7537590B2 (en) |
WO (1) | WO2006015299A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120123401A1 (en) * | 2009-07-27 | 2012-05-17 | Nova-b Ltd. | Methods and devices for tissue ablation |
US9024394B2 (en) | 2013-05-22 | 2015-05-05 | Transient Electronics, Inc. | Controlled transformation of non-transient electronics |
WO2017079758A1 (en) * | 2015-11-06 | 2017-05-11 | Bkr Ip Holdco Llc | Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device |
US9798886B2 (en) | 2015-07-08 | 2017-10-24 | International Business Machines Corporation | Bio-medical sensing platform |
EP3321899A1 (en) * | 2016-11-10 | 2018-05-16 | Therasolve NV | Electronic communication unit for an adhesive patch |
EP3421080A1 (en) * | 2017-06-28 | 2019-01-02 | Fundación Tecnalia Research & Innovation | Device and method for controlled and monitored transdermal delivery of active agents and use thereof |
WO2019099323A1 (en) * | 2017-11-14 | 2019-05-23 | E Ink California, Llc | Microcell systems for delivering hydrophilic active molecules |
US20200032925A1 (en) * | 2017-07-21 | 2020-01-30 | International Business Machines Corporation | Fluid delivery device with hydrophobic surface |
US10620151B2 (en) | 2016-08-30 | 2020-04-14 | Analog Devices Global | Electrochemical sensor, and a method of forming an electrochemical sensor |
US10646454B2 (en) | 2017-03-24 | 2020-05-12 | E Ink California, Llc | Microcell delivery systems including charged or magnetic particles for regulating rate of administration of actives |
US10702328B2 (en) | 2013-12-18 | 2020-07-07 | Novoxel Ltd. | Devices and methods for tissue vaporization |
US10933029B2 (en) | 2017-03-24 | 2021-03-02 | E Ink California, Llc | Microcell systems for delivering active molecules |
US11022579B2 (en) | 2018-02-05 | 2021-06-01 | Analog Devices International Unlimited Company | Retaining cap |
US11083515B2 (en) | 2013-12-18 | 2021-08-10 | Novoxel Ltd. | Methods and devices for thermal tissue vaporization and compression |
US11266832B2 (en) | 2017-11-14 | 2022-03-08 | E Ink California, Llc | Electrophoretic active delivery system including porous conductive electrode layer |
US11268927B2 (en) | 2016-08-30 | 2022-03-08 | Analog Devices International Unlimited Company | Electrochemical sensor, and a method of forming an electrochemical sensor |
US11648215B2 (en) | 2020-10-29 | 2023-05-16 | E Ink California, Llc | Microcell systems for delivering hydrophilic active molecules |
US11896723B2 (en) | 2020-10-29 | 2024-02-13 | E Ink Corporation | Microcell systems for delivering benefit agents |
US11938215B2 (en) | 2019-11-27 | 2024-03-26 | E Ink Corporation | Method for operating a benefit agent delivery system comprising microcells having an electrically eroding sealing layer |
Families Citing this family (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10010959A1 (en) * | 2000-03-06 | 2001-09-20 | Eppendorf Geraetebau Netheler | Transferring material through cell membranes, useful e.g. in genetic engineering or hydride production, using aqueous solution containing trehalose, increases cell survival |
US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US7787923B2 (en) * | 2003-11-26 | 2010-08-31 | Becton, Dickinson And Company | Fiber optic device for sensing analytes and method of making same |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
EP2671508B1 (en) | 2005-04-28 | 2020-09-16 | Proteus Digital Health, Inc. | Pharma-informatics system |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8372040B2 (en) | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
TWI419717B (en) * | 2005-06-17 | 2013-12-21 | Altea Therapeutics Corp | Permeant delivery system and methods for use thereof |
EP1905433A1 (en) * | 2005-07-15 | 2008-04-02 | Transcu Ltd. | Percutaneous absorption patch with application position indicating function, and iontophoresis device |
JP2007037868A (en) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | Transdermal administration device and its controlling method |
WO2007026671A1 (en) * | 2005-08-29 | 2007-03-08 | Transcu Ltd. | Iontophoresis device for selecting medicine to be administrated according to information from sensor |
CN101267896A (en) * | 2005-09-12 | 2008-09-17 | 阿尔扎公司 | Coatable transdermal delivery microprojection assembly |
WO2007032423A1 (en) * | 2005-09-16 | 2007-03-22 | Tti Ellebeau, Inc. | Catheter type iontophoresis apparatus |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
US20070093787A1 (en) * | 2005-09-30 | 2007-04-26 | Transcutaneous Technologies Inc. | Iontophoresis device to deliver multiple active agents to biological interfaces |
EP1928539A1 (en) * | 2005-09-30 | 2008-06-11 | Tti Ellebeau, Inc. | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
EP1941929A1 (en) * | 2005-09-30 | 2008-07-09 | Tti Ellebeau, Inc. | Electrode structure for iontophoresis comprising shape memory separator, and iontophoresis apparatus comprising the same |
US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
WO2007079116A1 (en) * | 2005-12-28 | 2007-07-12 | Tti Ellebeau, Inc. | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
US7848801B2 (en) | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
WO2007103070A2 (en) * | 2006-03-03 | 2007-09-13 | Genetronics, Inc. | Method and device for treating microscopic residual tumors remaining in tissues following surgical resection |
CA2647362C (en) | 2006-03-14 | 2014-10-14 | University Of Southern California | Mems device and method for delivery of therapeutic agents |
WO2007123707A1 (en) * | 2006-03-30 | 2007-11-01 | Tti Ellebeau, Inc. | Controlled release membrane and methods of use |
CN104138634B (en) * | 2006-04-13 | 2016-09-07 | 梯瓦制药国际有限责任公司 | The transdermal methods of delivery of anti-migraine compounds and system |
US9211212B2 (en) | 2006-04-20 | 2015-12-15 | Cerêve, Inc. | Apparatus and method for modulating sleep |
US9492313B2 (en) | 2006-04-20 | 2016-11-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Method and apparatus of noninvasive, regional brain thermal stimuli for the treatment of neurological disorders |
US8425583B2 (en) | 2006-04-20 | 2013-04-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia |
US11684510B2 (en) | 2006-04-20 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Noninvasive, regional brain thermal stimuli for the treatment of neurological disorders |
JP2009535082A (en) * | 2006-04-26 | 2009-10-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Apparatus for controlled release of substances and method of releasing substances |
US8017785B2 (en) * | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
TWI389889B (en) * | 2006-05-09 | 2013-03-21 | Targacept Inc | Novel polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
EP2034976A2 (en) * | 2006-07-05 | 2009-03-18 | Tti Ellebeau, Inc. | Delivery device having self-assembling dendritic polymers and method of use thereof |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
EP2043728A2 (en) * | 2006-07-11 | 2009-04-08 | Microchips, Inc. | Multi-reservoir pump device for dialysis, biosensing, or delivery of substances |
US20090326441A1 (en) * | 2006-08-01 | 2009-12-31 | Agency For Science ,Technology And Research | Ultrasonic Enhanced Microneedles |
US20080114282A1 (en) * | 2006-09-05 | 2008-05-15 | Transcu Ltd. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
RU2009112392A (en) * | 2006-09-05 | 2010-10-20 | ТиТиАй ЭЛЛЕБО, ИНК. (JP) | IMPEDANCE SYSTEMS, DEVICES AND METHODS FOR ASSESSING IONTOPHORETIC PROPERTIES OF COMPOUNDS |
BRPI0719353A2 (en) | 2006-12-01 | 2014-01-07 | Titi Ellebeau Inc | SYSTEMS, DEVICES AND METHODS FOR ENERGIZATION AND / OR CONTROL DEVICES, FOR EXAMPLE, TRANSDERMIC DISTRIBUTION DEVICES |
WO2008087884A1 (en) * | 2007-01-16 | 2008-07-24 | Tti Ellebeau, Inc. | Method for predicting medicament dose and program therefor |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
WO2008112578A1 (en) | 2007-03-09 | 2008-09-18 | Proteus Biomedical, Inc. | In-body device having a deployable antenna |
AU2008241470B2 (en) | 2007-04-16 | 2013-11-07 | Corium Pharma Solutions, Inc. | Solvent-cast microneedle arrays containing active |
AU2014200648B2 (en) * | 2007-04-16 | 2015-09-24 | Corium Pharma Solutions, Inc. | Solvent-cast microneedle arrays containing active |
US7998110B2 (en) * | 2007-04-25 | 2011-08-16 | Hong Kong Polytechnic University | Medical device for delivering drug and/or performing physical therapy |
US7853320B1 (en) | 2007-05-31 | 2010-12-14 | Purdue Pharma L.P. | Transdermal device having mechanical assist for porator-to-skin contact |
US8095213B1 (en) * | 2007-05-31 | 2012-01-10 | Purdue Pharma L.P. | Transdermal patch |
DE102007030710A1 (en) * | 2007-07-02 | 2009-01-08 | Robert Bosch Gmbh | Device for the storage and administration of active substances and a method for the administration of active substances by means of such a device |
US8047399B1 (en) | 2007-07-05 | 2011-11-01 | Purdue Pharma L.P. | Dispenser for transdermal devices |
RU2010107278A (en) * | 2007-07-31 | 2011-09-10 | Таргасепт, Инк. (Us) | TRANSDERMAL INTRODUCTION (2S) - (4E) -N-METHYL-5- (3- (5-ISOPROPOXYPYRIDINE) IL) -4-PENTEN-2-AMINE |
SG183726A1 (en) * | 2007-08-14 | 2012-09-27 | Hutchinson Fred Cancer Res | Needle array assembly and method for delivering therapeutic agents |
US7945320B2 (en) * | 2007-08-17 | 2011-05-17 | Isis Biopolymer, Inc. | Iontophoretic drug delivery system |
WO2009048607A1 (en) | 2007-10-10 | 2009-04-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
US20090247984A1 (en) * | 2007-10-24 | 2009-10-01 | Masimo Laboratories, Inc. | Use of microneedles for small molecule metabolite reporter delivery |
US9125979B2 (en) | 2007-10-25 | 2015-09-08 | Proteus Digital Health, Inc. | Fluid transfer port information system |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
US20100298808A1 (en) | 2007-11-28 | 2010-11-25 | Janisys Limited | Method and a delivery device for administering an active substance to a subject |
ES2425769T5 (en) | 2007-12-20 | 2017-07-28 | University Of Southern California | Apparatus for the administration of therapeutic agents |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US8486278B2 (en) | 2008-05-08 | 2013-07-16 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
EP2898911A1 (en) | 2008-05-08 | 2015-07-29 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
US20100022497A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject |
US20100022487A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20110190201A1 (en) * | 2008-07-24 | 2011-08-04 | Searete Llc | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20100022494A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
CA2734251A1 (en) | 2008-08-13 | 2010-02-18 | Proteus Biomedical, Inc. | Ingestible circuitry |
AU2009291764A1 (en) * | 2008-09-10 | 2010-03-18 | Transcu Ltd. | Apparatus and method to dispense HPC-based viscous liquids into porous substrates, e.g., continuous web-based process |
US20100068283A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex VIVO modifiable particle or polymeric material medicament carrier |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068152A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable particle or polymeric based final dosage form |
NZ591834A (en) * | 2008-10-02 | 2011-12-22 | Mylan Inc | Method of making a multilayer adhesive laminate |
US9480795B2 (en) * | 2009-01-21 | 2016-11-01 | Palo Alto Research Center Incorporated | Sensor system for drug delivery device, drug delivery device having the same and method of using the same |
US8236238B2 (en) * | 2009-01-21 | 2012-08-07 | Palo Alto Research Center Incorporated | Drug deactivation system |
US7838715B2 (en) * | 2009-01-21 | 2010-11-23 | Palo Alto Research Center Incorporated | Drug deactivation system and method of deactivating a drug using the same |
US8807169B2 (en) | 2009-02-12 | 2014-08-19 | Picolife Technologies, Llc | Flow control system for a micropump |
US20110105951A1 (en) * | 2009-10-30 | 2011-05-05 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
WO2010101626A1 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Techniques and devices associated with blood sampling |
US9119578B2 (en) | 2011-04-29 | 2015-09-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
ES2660674T3 (en) | 2009-03-04 | 2018-03-23 | Emplicure Ab | Abuse Resistant Formulation |
US8540664B2 (en) | 2009-03-25 | 2013-09-24 | Proteus Digital Health, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
JP5820805B2 (en) * | 2009-04-24 | 2015-11-24 | コリウム インターナショナル, インコーポレイテッド | Process for manufacturing microprojection arrays |
CN102458236B (en) | 2009-04-28 | 2016-01-27 | 普罗秋斯数字健康公司 | The Ingestible event marker of high reliability and using method thereof |
WO2010129928A1 (en) * | 2009-05-08 | 2010-11-11 | Isis Biopolymer Llc | Iontophoretic device with improved counterelectrode |
EP2427177B1 (en) | 2009-05-08 | 2018-03-28 | Emplicure AB | Composition for sustained drug delivery comprising geopolymeric binder |
US20110092881A1 (en) * | 2009-05-08 | 2011-04-21 | Isis Biopolymer Inc. | Iontophoretic device with contact sensor |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
EP2467797B1 (en) | 2009-08-18 | 2017-07-19 | MiniPumps, LLC | Electrolytic drug-delivery pump with adaptive control |
US20130018279A1 (en) * | 2009-09-01 | 2013-01-17 | Pathway Genomics | "blood sample collection apparatus and kits" |
EP2473226A1 (en) * | 2009-09-04 | 2012-07-11 | Minipumps LLC | Adhesive skin patch with pump for subcutaneous drug delivery |
US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US8882748B2 (en) | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
KR101032298B1 (en) | 2009-10-27 | 2011-05-06 | (주)유 바이오메드 | Micro needle apparatus for injecting various kinds of fluid |
US9078863B2 (en) * | 2009-11-13 | 2015-07-14 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
US8439896B2 (en) * | 2009-11-13 | 2013-05-14 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
US8894630B2 (en) | 2009-11-13 | 2014-11-25 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
EP2531096A4 (en) | 2010-02-01 | 2013-09-11 | Proteus Digital Health Inc | Two-wrist data gathering system |
US9014779B2 (en) | 2010-02-01 | 2015-04-21 | Proteus Digital Health, Inc. | Data gathering system |
KR20170121299A (en) | 2010-04-07 | 2017-11-01 | 프로테우스 디지털 헬스, 인코포레이티드 | Miniature ingestible device |
CN102985131B (en) | 2010-04-28 | 2016-06-29 | 金伯利-克拉克环球有限公司 | For delivering the medical treatment device of siRNA |
US9586044B2 (en) | 2010-04-28 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Method for increasing the permeability of an epithelial barrier |
PT2563450T (en) | 2010-04-28 | 2017-08-28 | Kimberly Clark Co | Device for delivery of rheumatoid arthritis medication |
JP5860453B2 (en) | 2010-04-28 | 2016-02-16 | キンバリー クラーク ワールドワイド インコーポレイテッド | Composite microneedle array with nanostructures on the surface |
AU2011248108B2 (en) | 2010-05-04 | 2016-05-26 | Corium Pharma Solutions, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
MX2012013193A (en) | 2010-05-20 | 2012-12-17 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines. |
AU2011265005B2 (en) | 2010-06-07 | 2015-04-09 | Amgen Inc. | Drug delivery device |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
WO2012015756A2 (en) * | 2010-07-29 | 2012-02-02 | Proteus Biomedical, Inc. | Hybrid housing for implantable medical device |
US9322103B2 (en) | 2010-08-06 | 2016-04-26 | Microchips Biotech, Inc. | Biosensor membrane composition, biosensor, and methods for making same |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
KR20140003405A (en) * | 2010-09-07 | 2014-01-09 | 오렉쏘 에이비 | A transdermal drug administration device |
US8808202B2 (en) | 2010-11-09 | 2014-08-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | Ingestible device with medicinal product |
WO2012071514A1 (en) * | 2010-11-23 | 2012-05-31 | Fred Hutchinson Cancer Research Center | Therapeutic methods for solid delivery |
CA2816883A1 (en) * | 2010-11-23 | 2012-05-31 | Presage Biosciences, Inc. | Therapeutic methods and compositions for solid delivery |
US8696637B2 (en) | 2011-02-28 | 2014-04-15 | Kimberly-Clark Worldwide | Transdermal patch containing microneedles |
EP3106092A3 (en) | 2011-04-29 | 2017-03-08 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
KR102237667B1 (en) | 2011-04-29 | 2021-04-12 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
US8636696B2 (en) | 2011-06-10 | 2014-01-28 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
US10427153B2 (en) | 2011-08-25 | 2019-10-01 | Microchips Biotech, Inc. | Systems and methods for sealing a plurality of reservoirs of a microchip element with a sealing grid |
AU2012298659B2 (en) | 2011-08-25 | 2017-02-02 | Microchips Biotech, Inc. | Space-efficient containment devices and method of making same |
US20130090633A1 (en) * | 2011-10-07 | 2013-04-11 | University Of Southern California | Osmotic patch pump |
PL3542851T3 (en) | 2011-10-27 | 2022-04-25 | Sorrento Therapeutics, Inc. | Implantable devices for delivery of bioactive agents |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
EP3574950B1 (en) | 2011-10-27 | 2021-02-17 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
CN104023760A (en) | 2011-10-28 | 2014-09-03 | 普莱萨格生命科学公司 | Methods for drug delivery |
US8771229B2 (en) | 2011-12-01 | 2014-07-08 | Picolife Technologies, Llc | Cartridge system for delivery of medicament |
US8790307B2 (en) | 2011-12-01 | 2014-07-29 | Picolife Technologies, Llc | Drug delivery device and methods therefor |
FR2986156B1 (en) | 2012-01-30 | 2014-07-04 | Rhenovia Pharma | TRANSDERMIC DEVICE FOR CONTROLLED ADMINISTRATION TO A PATIENT OF AT LEAST ONE ACTIVE INGREDIENT |
US10130759B2 (en) | 2012-03-09 | 2018-11-20 | Picolife Technologies, Llc | Multi-ported drug delivery device having multi-reservoir cartridge system |
WO2013151766A1 (en) * | 2012-04-02 | 2013-10-10 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure by intradermal infusion |
US9883834B2 (en) | 2012-04-16 | 2018-02-06 | Farid Amirouche | Medication delivery device with multi-reservoir cartridge system and related methods of use |
US10245420B2 (en) | 2012-06-26 | 2019-04-02 | PicoLife Technologies | Medicament distribution systems and related methods of use |
ES2957540T3 (en) * | 2012-07-10 | 2024-01-22 | Massachusetts Gen Hospital | System and method for monitoring and treating a surface of a subject |
KR20150038038A (en) | 2012-07-23 | 2015-04-08 | 프로테우스 디지털 헬스, 인코포레이티드 | Techniques for manufacturing ingestible event markers comprising an ingestible component |
US20150217002A1 (en) * | 2012-08-10 | 2015-08-06 | The Research Foundation For The State University Of New York | Near-infrared spectroscopy and optical reporter |
US20140088345A1 (en) * | 2012-09-27 | 2014-03-27 | Palo Alto Research Center Incorporated | Single channel, multiple drug delivery device and methods |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
US9005108B2 (en) * | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
UA116783C2 (en) | 2012-10-18 | 2018-05-10 | Протеус Діджитал Хелс, Інк. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
EP2908853B1 (en) | 2012-10-21 | 2018-12-05 | University Of Rochester | Thy1 (cd90) as a therapy to control adipose tissue accumulation |
KR102265808B1 (en) | 2012-12-21 | 2021-06-16 | 코리움, 인크. | Microarray for delivery of therapeutic agent and methods of use |
CN104869888B (en) * | 2012-12-21 | 2017-12-19 | 微芯片生物技术公司 | Implantable medical device for minimally invasive insertion |
CA2896950C (en) | 2013-01-02 | 2021-10-19 | Cereve, Inc. | Systems for enhancing sleep |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
EP2943479B1 (en) | 2013-01-11 | 2020-04-15 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
US20140207047A1 (en) * | 2013-01-22 | 2014-07-24 | Chrono Therapeutics, Inc. | Transdermal drug delivery system and method |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
TWI659994B (en) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
CN105073179B (en) | 2013-02-28 | 2019-03-19 | 索伦托治疗有限公司 | Transdermal drug delivery devices |
EP2961469A4 (en) | 2013-02-28 | 2016-10-26 | Kimberly Clark Co | Drug delivery device |
CN104994901B (en) | 2013-02-28 | 2019-06-28 | 微芯片生物技术公司 | Implantable medical device for minimally invasive insertion |
JP6487899B2 (en) | 2013-03-12 | 2019-03-20 | コリウム インターナショナル, インコーポレイテッド | Microprojection applicator |
EP4194028A1 (en) | 2013-03-15 | 2023-06-14 | Corium Pharma Solutions, Inc. | Multiple impact microprojection applicators |
MX2015012933A (en) | 2013-03-15 | 2016-09-19 | Corium Int Inc | Microarray for delivery of therapeutic agent and methods of use. |
WO2014144738A1 (en) | 2013-03-15 | 2014-09-18 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
AU2014233541B2 (en) | 2013-03-15 | 2018-11-22 | Corium Pharma Solutions, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
CA2904121C (en) * | 2013-03-15 | 2021-02-23 | Becton, Dickinson And Company | Smart adapter for infusion devices |
JP2016514133A (en) | 2013-03-15 | 2016-05-19 | コリウム インターナショナル, インコーポレイテッド | MICROARRAY CONTAINING FINE STRUCTURE CONTAINING NO POLYMER, MANUFACTURING METHOD AND USE METHOD |
US10610416B2 (en) | 2013-03-15 | 2020-04-07 | Adaco Innovations, Llc | System, method, and product for an adhesive strip configured to selectively dispense a fluid |
CN105555336B (en) | 2013-08-05 | 2019-04-30 | 康迈德医疗器械有限公司 | The patch pump of compliance |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
FR3014321B1 (en) * | 2013-12-11 | 2018-03-23 | Albea Services | TREATMENT MODULE, IN PARTICULAR FOR A COSMETIC AND / OR PHARMACEUTICAL PRODUCT AND A COSMETIC SYSTEM COMPRISING SUCH A TREATMENT MODULE |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
FI127226B (en) | 2013-12-20 | 2018-01-31 | Teknologian Tutkimuskeskus Vtt Oy | METHOD AND APPARATUS FOR SKIN TREATMENT |
KR101967133B1 (en) * | 2014-04-22 | 2019-04-10 | 한국과학기술원 | Method for manufacturing a flexible drug delivery device and the flexible drug delivery device manufactured by the same |
CA2945351C (en) | 2014-04-30 | 2017-09-05 | Kimberly-Clark Worldwide, Inc. | Controller portion of transdermal drug delivery apparatus and methods |
MX2016013612A (en) | 2014-04-30 | 2017-02-02 | Kimberly Clark Co | Receptacle portion of transdermal drug delivery apparatus and methods. |
EP3137153A4 (en) | 2014-04-30 | 2017-11-29 | Kimberly-Clark Worldwide, Inc. | Transdermal drug delivery apparatus and methods |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
US9937124B2 (en) * | 2014-09-11 | 2018-04-10 | International Business Machines Corporation | Microchip substance delivery devices having low-power electromechanical release mechanisms |
WO2016123241A1 (en) * | 2015-01-27 | 2016-08-04 | Cerêve, Inc. | Method and apparatuses for modulating sleep by chemical activation of temperature receptors |
JP2018511355A (en) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Drug delivery method and system |
EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
JP6760282B2 (en) * | 2015-07-07 | 2020-09-23 | 凸版印刷株式会社 | Transdermal administration device |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
US10945724B2 (en) * | 2015-09-25 | 2021-03-16 | Microkoll, Inc. | Apparatus and methods for adhesion |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
KR102215238B1 (en) | 2016-07-22 | 2021-02-22 | 프로테우스 디지털 헬스, 인코포레이티드 | Electromagnetic sensing and detection of ingestible event markers |
US10821297B2 (en) | 2016-09-30 | 2020-11-03 | Johnson & Johnson Consumer Inc. | Kit and method for topical delivery of benefits |
IL265827B2 (en) | 2016-10-26 | 2023-03-01 | Proteus Digital Health Inc | Methods for manufacturing capsules with ingestible event markers |
WO2018093218A1 (en) * | 2016-11-18 | 2018-05-24 | 연세대학교 산학협력단 | Microneedle array with composite formulation, and method for manufacturing same |
KR20190088073A (en) * | 2016-12-16 | 2019-07-25 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Attachment band for fluid delivery device and method of using same |
AU2017387141A1 (en) | 2016-12-29 | 2019-07-18 | Pure Ratios Holdings, Inc. | Modular transdermal delivery system and associated methods of manufacture and use |
EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
KR101832750B1 (en) * | 2017-04-13 | 2018-02-27 | 주식회사 톡톡코리아 | Micro needle devices of injecting medicine |
US10737090B2 (en) | 2017-07-11 | 2020-08-11 | Medtronic, Inc. | External defibrillation electrode conductive electrolyte dispersal pad |
US11532389B1 (en) | 2017-09-07 | 2022-12-20 | Massachusetts Mutual Life Insurance Company | System and method for personalized transdermal drug delivery |
BR112020004670A2 (en) * | 2017-09-12 | 2020-09-15 | Lts Lohmann Therapie-Systeme Ag | iontophoretic microneedle device |
US11251635B2 (en) | 2017-12-19 | 2022-02-15 | Welch Allyn, Inc. | Vital signs monitor with a removable and dischargable battery |
CN108403297A (en) * | 2018-03-12 | 2018-08-17 | 南京理工大学 | A kind of intelligence dressing and preparation method thereof |
US11583633B2 (en) | 2018-04-03 | 2023-02-21 | Amgen Inc. | Systems and methods for delayed drug delivery |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
US11213667B2 (en) | 2018-07-11 | 2022-01-04 | Santa Clara University | 3D printed microneedles for microencapsulated mammalian cell extrusion |
EP4308088A4 (en) | 2021-11-08 | 2024-06-12 | Weiyong Li | Transdermal drug delivery system for delivering a drug to a patient |
CN114305868A (en) * | 2021-12-30 | 2022-04-12 | 康宇辰 | Epoxy sterilization wound dressing |
Citations (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692027A (en) * | 1971-04-23 | 1972-09-19 | Everett H Ellinwood Jr | Implanted medication dispensing device and method |
US3952741A (en) * | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4003379A (en) * | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US4507115A (en) * | 1981-04-01 | 1985-03-26 | Olympus Optical Co., Ltd. | Medical capsule device |
US4585652A (en) * | 1984-11-19 | 1986-04-29 | Regents Of The University Of Minnesota | Electrochemical controlled release drug delivery system |
US4731049A (en) * | 1987-01-30 | 1988-03-15 | Ionics, Incorporated | Cell for electrically controlled transdermal drug delivery |
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US4994023A (en) * | 1989-08-08 | 1991-02-19 | Wellinghoff Stephen T | Electrochemical drug release and article |
US5041107A (en) * | 1989-10-06 | 1991-08-20 | Cardiac Pacemakers, Inc. | Electrically controllable, non-occluding, body implantable drug delivery system |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US5045059A (en) * | 1989-02-15 | 1991-09-03 | Alza Corporation | Intravenous system for delivering a beneficial agent |
US5147297A (en) * | 1990-05-07 | 1992-09-15 | Alza Corporation | Iontophoretic delivery device |
US5196002A (en) * | 1990-10-09 | 1993-03-23 | University Of Utah Research Foundation | Implantable drug delivery system with piston acutation |
US5200051A (en) * | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5202018A (en) * | 1990-07-12 | 1993-04-13 | Semilab Felvezeto Fizikai Labortorium Rt. | Process for electrochemical dissolution of semiconductors |
US5252294A (en) * | 1988-06-01 | 1993-10-12 | Messerschmitt-Bolkow-Blohm Gmbh | Micromechanical structure |
US5254081A (en) * | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
US5288504A (en) * | 1988-09-09 | 1994-02-22 | The Ronald T. Dodge Company | Pharmaceuticals microencapsulated by vapor deposited polymers and method |
US5318557A (en) * | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
US5336213A (en) * | 1992-04-08 | 1994-08-09 | International Medical Associates, Inc. | Selectable dosage transdermal delivery system |
US5386419A (en) * | 1992-08-20 | 1995-01-31 | U.S. Philips Corporation | Multiplexer for at least two independently operating signal sources |
US5427585A (en) * | 1993-03-29 | 1995-06-27 | Bettinger; David S. | On-demand iontophoretic system |
US5429822A (en) * | 1992-03-13 | 1995-07-04 | Cambridge Scientific, Inc. | Biodegradable bursting release system |
US5443508A (en) * | 1993-03-01 | 1995-08-22 | Giampapa; Vincent C. | Subcutaneous implantable multiple agent delivery system |
US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5533995A (en) * | 1991-11-13 | 1996-07-09 | Elan Corporation, Plc | Passive transdermal device with controlled drug delivery |
US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US5782799A (en) * | 1997-02-07 | 1998-07-21 | Sarcos, Inc. | Method for automatic dosing of drugs |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5824204A (en) * | 1996-06-27 | 1998-10-20 | Ic Sensors, Inc. | Micromachined capillary electrophoresis device |
US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US5925069A (en) * | 1997-11-07 | 1999-07-20 | Sulzer Intermedics Inc. | Method for preparing a high definition window in a conformally coated medical device |
US5957579A (en) * | 1997-10-09 | 1999-09-28 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6066163A (en) * | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US6068752A (en) * | 1997-04-25 | 2000-05-30 | Caliper Technologies Corp. | Microfluidic devices incorporating improved channel geometries |
US6083763A (en) * | 1996-12-31 | 2000-07-04 | Genometrix Inc. | Multiplexed molecular analysis apparatus and method |
US6096656A (en) * | 1999-06-24 | 2000-08-01 | Sandia Corporation | Formation of microchannels from low-temperature plasma-deposited silicon oxynitride |
US6114658A (en) * | 1996-03-15 | 2000-09-05 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Device for the encapsulated reception of a material |
US6171850B1 (en) * | 1999-03-08 | 2001-01-09 | Caliper Technologies Corp. | Integrated devices and systems for performing temperature controlled reactions and analyses |
US6219574B1 (en) * | 1996-06-18 | 2001-04-17 | Alza Corporation | Device and method for enchancing transdermal sampling |
US6232150B1 (en) * | 1998-12-03 | 2001-05-15 | The Regents Of The University Of Michigan | Process for making microstructures and microstructures made thereby |
US6243608B1 (en) * | 1998-06-12 | 2001-06-05 | Intermedics Inc. | Implantable device with optical telemetry |
US6261584B1 (en) * | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6264990B1 (en) * | 1996-10-16 | 2001-07-24 | Alza Corporation | Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. |
US6303420B1 (en) * | 1999-08-13 | 2001-10-16 | Texas Instruments Incorporated | Integrated bipolar junction transistor for mixed signal circuits |
US6334856B1 (en) * | 1998-06-10 | 2002-01-01 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US6349232B1 (en) * | 1997-07-11 | 2002-02-19 | Pets 'n People Ltd. | Apparatus and method for dispensing pet care substances |
US20020022826A1 (en) * | 2000-08-14 | 2002-02-21 | Reynolds John R. | Burst electrode |
US6366794B1 (en) * | 1998-11-20 | 2002-04-02 | The University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
US6377847B1 (en) * | 1993-09-30 | 2002-04-23 | Vyteris, Inc. | Iontophoretic drug delivery device and reservoir and method of making same |
US20020072784A1 (en) * | 2000-10-10 | 2002-06-13 | Sheppard Norman F. | Microchip reservoir devices using wireless transmission of power and data |
US20020082527A1 (en) * | 1998-01-12 | 2002-06-27 | Jin Liu | Assessment and control of acoustic tissue effects |
US20020099359A1 (en) * | 2001-01-09 | 2002-07-25 | Santini John T. | Flexible microchip devices for ophthalmic and other applications |
US20020119176A1 (en) * | 2001-02-28 | 2002-08-29 | Greenberg Robert J. | Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating |
US20020121486A1 (en) * | 2000-07-17 | 2002-09-05 | Verdegaal Russell J. | Method of treating agricultural equipment, alleys and lagoons in confined animal feeding operations |
US20020161352A1 (en) * | 2001-04-25 | 2002-10-31 | Lin Chen Hai | Vaginal ring preparation and application |
US6517864B1 (en) * | 1998-08-27 | 2003-02-11 | Pharmacia Ab | Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
US6527762B1 (en) * | 1999-08-18 | 2003-03-04 | Microchips, Inc. | Thermally-activated microchip chemical delivery devices |
US6537256B2 (en) * | 1999-11-17 | 2003-03-25 | Microchips, Inc. | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6537250B1 (en) * | 1997-08-27 | 2003-03-25 | Science, Incorporated | Fluid delivery device with electrically activated energy source |
US20030069560A1 (en) * | 2001-05-03 | 2003-04-10 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US6551838B2 (en) * | 2000-03-02 | 2003-04-22 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
US6558321B1 (en) * | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6571125B2 (en) * | 2001-02-12 | 2003-05-27 | Medtronic, Inc. | Drug delivery device |
US6620123B1 (en) * | 1999-12-17 | 2003-09-16 | Sontra Medical, Inc. | Method and apparatus for producing homogenous cavitation to enhance transdermal transport |
US20030176854A1 (en) * | 2002-03-11 | 2003-09-18 | Alcon, Inc. | Implantable drug delivery system |
US6676363B1 (en) * | 1999-01-05 | 2004-01-13 | Jean-Pierre Solignac | Manipulator robot and installation comprising same |
US20040043042A1 (en) * | 2001-12-03 | 2004-03-04 | Johnson Audrey M. | Microscale lyophilization and drying methods for the stabilization of molecules |
US6702857B2 (en) * | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
US20040082937A1 (en) * | 2002-09-04 | 2004-04-29 | Dennis Ausiello | Method and device for the controlled delivery of parathyroid hormone |
US6730072B2 (en) * | 2000-05-30 | 2004-05-04 | Massachusetts Institute Of Technology | Methods and devices for sealing microchip reservoir devices |
US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US20040106904A1 (en) * | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
US20040106914A1 (en) * | 2002-09-23 | 2004-06-03 | Coppeta Jonathan R. | Micro-reservoir osmotic release systems and microtube array device |
US20040106953A1 (en) * | 2002-10-04 | 2004-06-03 | Yomtov Barry M. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
US20040121486A1 (en) * | 2002-08-16 | 2004-06-24 | Uhland Scott A. | Controlled release device and method using electrothermal ablation |
US6756053B2 (en) * | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
US20040127942A1 (en) * | 2002-10-04 | 2004-07-01 | Yomtov Barry M. | Medical device for neural stimulation and controlled drug delivery |
US6773429B2 (en) * | 2000-10-11 | 2004-08-10 | Microchips, Inc. | Microchip reservoir devices and facilitated corrosion of electrodes |
US20040166140A1 (en) * | 1996-07-02 | 2004-08-26 | Santini John T. | Implantable device for controlled release of drug |
US20050050859A1 (en) * | 2003-07-17 | 2005-03-10 | Coppeta Jonathan R. | Low temperature methods for hermetically sealing reservoir devices |
US20050055014A1 (en) * | 2003-08-04 | 2005-03-10 | Coppeta Jonathan R. | Methods for accelerated release of material from a reservoir device |
US6875208B2 (en) * | 2001-05-31 | 2005-04-05 | Massachusetts Institute Of Technology | Microchip devices with improved reservoir opening |
US20050077584A1 (en) * | 2001-06-28 | 2005-04-14 | Uhland Scott A. | Hermetically sealed microchip reservoir devices |
US20050096587A1 (en) * | 2003-11-03 | 2005-05-05 | Santini John T.Jr. | Medical device for sensing glucose |
US20050100937A1 (en) * | 2003-09-11 | 2005-05-12 | Holmes Elizabeth A. | Medical device for analyte monitoring and drug delivery |
US20050267440A1 (en) * | 2004-06-01 | 2005-12-01 | Herman Stephen J | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
US7004928B2 (en) * | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2295792A1 (en) * | 1974-12-24 | 1976-07-23 | Commissariat Energie Atomique | PROCESS FOR THE PREPARATION OF COMPOUND SEMICONDUCTORS |
US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
US4856188A (en) | 1984-10-12 | 1989-08-15 | Drug Delivery Systems Inc. | Method for making disposable and/or replenishable transdermal drug applicators |
GB8422876D0 (en) | 1984-09-11 | 1984-10-17 | Secr Defence | Silicon implant devices |
US5387419A (en) | 1988-03-31 | 1995-02-07 | The University Of Michigan | System for controlled release of antiarrhythmic agents |
US5170801A (en) | 1990-10-02 | 1992-12-15 | Glaxo Inc. | Medical capsule device actuated by radio-frequency (rf) signal |
US5167625A (en) | 1990-10-09 | 1992-12-01 | Sarcos Group | Multiple vesicle implantable drug delivery system |
US5368588A (en) | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
US5366454A (en) | 1993-03-17 | 1994-11-22 | La Corporation De L'ecole Polytechnique | Implantable medication dispensing device |
US5474527A (en) | 1993-03-29 | 1995-12-12 | Bettinger; David S. | Positive displacement transdermal system |
US5368704A (en) | 1993-08-06 | 1994-11-29 | Teknekron Corporation | Micro-electrochemical valves and method |
JP3488465B2 (en) | 1993-10-28 | 2004-01-19 | ヒューストン・アドバンスド・リサーチ・センター | Microfabricated flow-through porosity device for separately detecting binding reactions |
US5837276A (en) * | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US5585069A (en) | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
US5992769A (en) | 1995-06-09 | 1999-11-30 | The Regents Of The University Of Michigan | Microchannel system for fluid delivery |
US6041253A (en) | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
US6234990B1 (en) | 1996-06-28 | 2001-05-22 | Sontra Medical, Inc. | Ultrasound enhancement of transdermal transport |
US6001090A (en) | 1998-02-09 | 1999-12-14 | Lenhart; Douglas | Thermal pharmaceutical delivery system |
US6808522B2 (en) * | 1999-12-10 | 2004-10-26 | Massachusetts Institute Of Technology | Microchip devices for delivery of molecules and methods of fabrication thereof |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
US6632606B1 (en) * | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
US6629968B1 (en) * | 2000-06-30 | 2003-10-07 | Vyteris, Inc. | Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system incorporating the reservoir-electrode |
KR100463194B1 (en) | 2001-02-16 | 2004-12-23 | 삼성전자주식회사 | Method for programming a nand-type flash memory |
US6663615B1 (en) | 2001-09-04 | 2003-12-16 | The Ohio State University | Dual stage microvalve and method of use |
-
2005
- 2005-08-01 US US11/194,157 patent/US7537590B2/en not_active Expired - Fee Related
- 2005-08-01 WO PCT/US2005/027201 patent/WO2006015299A2/en active Application Filing
-
2009
- 2009-05-26 US US12/471,973 patent/US20090234214A1/en not_active Abandoned
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692027A (en) * | 1971-04-23 | 1972-09-19 | Everett H Ellinwood Jr | Implanted medication dispensing device and method |
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4003379A (en) * | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US3952741A (en) * | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US3952741B1 (en) * | 1975-01-09 | 1983-01-18 | ||
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US4507115A (en) * | 1981-04-01 | 1985-03-26 | Olympus Optical Co., Ltd. | Medical capsule device |
US4585652A (en) * | 1984-11-19 | 1986-04-29 | Regents Of The University Of Minnesota | Electrochemical controlled release drug delivery system |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US4731049A (en) * | 1987-01-30 | 1988-03-15 | Ionics, Incorporated | Cell for electrically controlled transdermal drug delivery |
US5252294A (en) * | 1988-06-01 | 1993-10-12 | Messerschmitt-Bolkow-Blohm Gmbh | Micromechanical structure |
US5288504A (en) * | 1988-09-09 | 1994-02-22 | The Ronald T. Dodge Company | Pharmaceuticals microencapsulated by vapor deposited polymers and method |
US5200051A (en) * | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5045059A (en) * | 1989-02-15 | 1991-09-03 | Alza Corporation | Intravenous system for delivering a beneficial agent |
US4994023A (en) * | 1989-08-08 | 1991-02-19 | Wellinghoff Stephen T | Electrochemical drug release and article |
US5041107A (en) * | 1989-10-06 | 1991-08-20 | Cardiac Pacemakers, Inc. | Electrically controllable, non-occluding, body implantable drug delivery system |
US5147297A (en) * | 1990-05-07 | 1992-09-15 | Alza Corporation | Iontophoretic delivery device |
US5202018A (en) * | 1990-07-12 | 1993-04-13 | Semilab Felvezeto Fizikai Labortorium Rt. | Process for electrochemical dissolution of semiconductors |
US5196002A (en) * | 1990-10-09 | 1993-03-23 | University Of Utah Research Foundation | Implantable drug delivery system with piston acutation |
US5254081A (en) * | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
US5533995A (en) * | 1991-11-13 | 1996-07-09 | Elan Corporation, Plc | Passive transdermal device with controlled drug delivery |
US5429822A (en) * | 1992-03-13 | 1995-07-04 | Cambridge Scientific, Inc. | Biodegradable bursting release system |
US5336213A (en) * | 1992-04-08 | 1994-08-09 | International Medical Associates, Inc. | Selectable dosage transdermal delivery system |
US5318557A (en) * | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
US5386419A (en) * | 1992-08-20 | 1995-01-31 | U.S. Philips Corporation | Multiplexer for at least two independently operating signal sources |
US5443508A (en) * | 1993-03-01 | 1995-08-22 | Giampapa; Vincent C. | Subcutaneous implantable multiple agent delivery system |
US5427585A (en) * | 1993-03-29 | 1995-06-27 | Bettinger; David S. | On-demand iontophoretic system |
US6377847B1 (en) * | 1993-09-30 | 2002-04-23 | Vyteris, Inc. | Iontophoretic drug delivery device and reservoir and method of making same |
US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US6756053B2 (en) * | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
US6261584B1 (en) * | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6066163A (en) * | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US6114658A (en) * | 1996-03-15 | 2000-09-05 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Device for the encapsulated reception of a material |
US6230051B1 (en) * | 1996-06-18 | 2001-05-08 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
US6219574B1 (en) * | 1996-06-18 | 2001-04-17 | Alza Corporation | Device and method for enchancing transdermal sampling |
US5824204A (en) * | 1996-06-27 | 1998-10-20 | Ic Sensors, Inc. | Micromachined capillary electrophoresis device |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US20040166140A1 (en) * | 1996-07-02 | 2004-08-26 | Santini John T. | Implantable device for controlled release of drug |
US6123861A (en) * | 1996-07-02 | 2000-09-26 | Massachusetts Institute Of Technology | Fabrication of microchip drug delivery devices |
US6264990B1 (en) * | 1996-10-16 | 2001-07-24 | Alza Corporation | Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. |
US6083763A (en) * | 1996-12-31 | 2000-07-04 | Genometrix Inc. | Multiplexed molecular analysis apparatus and method |
US5782799A (en) * | 1997-02-07 | 1998-07-21 | Sarcos, Inc. | Method for automatic dosing of drugs |
US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US6558321B1 (en) * | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6068752A (en) * | 1997-04-25 | 2000-05-30 | Caliper Technologies Corp. | Microfluidic devices incorporating improved channel geometries |
US6349232B1 (en) * | 1997-07-11 | 2002-02-19 | Pets 'n People Ltd. | Apparatus and method for dispensing pet care substances |
US6537250B1 (en) * | 1997-08-27 | 2003-03-25 | Science, Incorporated | Fluid delivery device with electrically activated energy source |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US5957579A (en) * | 1997-10-09 | 1999-09-28 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
US5925069A (en) * | 1997-11-07 | 1999-07-20 | Sulzer Intermedics Inc. | Method for preparing a high definition window in a conformally coated medical device |
US20020082527A1 (en) * | 1998-01-12 | 2002-06-27 | Jin Liu | Assessment and control of acoustic tissue effects |
US6334856B1 (en) * | 1998-06-10 | 2002-01-01 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6243608B1 (en) * | 1998-06-12 | 2001-06-05 | Intermedics Inc. | Implantable device with optical telemetry |
US6517864B1 (en) * | 1998-08-27 | 2003-02-11 | Pharmacia Ab | Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
US6366794B1 (en) * | 1998-11-20 | 2002-04-02 | The University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
US6232150B1 (en) * | 1998-12-03 | 2001-05-15 | The Regents Of The University Of Michigan | Process for making microstructures and microstructures made thereby |
US6676363B1 (en) * | 1999-01-05 | 2004-01-13 | Jean-Pierre Solignac | Manipulator robot and installation comprising same |
US6171850B1 (en) * | 1999-03-08 | 2001-01-09 | Caliper Technologies Corp. | Integrated devices and systems for performing temperature controlled reactions and analyses |
US6096656A (en) * | 1999-06-24 | 2000-08-01 | Sandia Corporation | Formation of microchannels from low-temperature plasma-deposited silicon oxynitride |
US6303420B1 (en) * | 1999-08-13 | 2001-10-16 | Texas Instruments Incorporated | Integrated bipolar junction transistor for mixed signal circuits |
US20030105455A1 (en) * | 1999-08-18 | 2003-06-05 | Santini John T. | Thermally-activated microchip chemical delivery devices |
US6527762B1 (en) * | 1999-08-18 | 2003-03-04 | Microchips, Inc. | Thermally-activated microchip chemical delivery devices |
US6537256B2 (en) * | 1999-11-17 | 2003-03-25 | Microchips, Inc. | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6620123B1 (en) * | 1999-12-17 | 2003-09-16 | Sontra Medical, Inc. | Method and apparatus for producing homogenous cavitation to enhance transdermal transport |
US6849463B2 (en) * | 2000-03-02 | 2005-02-01 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
US6551838B2 (en) * | 2000-03-02 | 2003-04-22 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
US6730072B2 (en) * | 2000-05-30 | 2004-05-04 | Massachusetts Institute Of Technology | Methods and devices for sealing microchip reservoir devices |
US20020121486A1 (en) * | 2000-07-17 | 2002-09-05 | Verdegaal Russell J. | Method of treating agricultural equipment, alleys and lagoons in confined animal feeding operations |
US20020022826A1 (en) * | 2000-08-14 | 2002-02-21 | Reynolds John R. | Burst electrode |
US20020072784A1 (en) * | 2000-10-10 | 2002-06-13 | Sheppard Norman F. | Microchip reservoir devices using wireless transmission of power and data |
US6773429B2 (en) * | 2000-10-11 | 2004-08-10 | Microchips, Inc. | Microchip reservoir devices and facilitated corrosion of electrodes |
US20020099359A1 (en) * | 2001-01-09 | 2002-07-25 | Santini John T. | Flexible microchip devices for ophthalmic and other applications |
US6571125B2 (en) * | 2001-02-12 | 2003-05-27 | Medtronic, Inc. | Drug delivery device |
US20020119176A1 (en) * | 2001-02-28 | 2002-08-29 | Greenberg Robert J. | Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating |
US20020161352A1 (en) * | 2001-04-25 | 2002-10-31 | Lin Chen Hai | Vaginal ring preparation and application |
US20030069560A1 (en) * | 2001-05-03 | 2003-04-10 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US20050143715A1 (en) * | 2001-05-31 | 2005-06-30 | Cima Michael J. | Device for controlled reservoir opening with reinforced reservoir caps |
US6875208B2 (en) * | 2001-05-31 | 2005-04-05 | Massachusetts Institute Of Technology | Microchip devices with improved reservoir opening |
US20050077584A1 (en) * | 2001-06-28 | 2005-04-14 | Uhland Scott A. | Hermetically sealed microchip reservoir devices |
US6702857B2 (en) * | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
US20040043042A1 (en) * | 2001-12-03 | 2004-03-04 | Johnson Audrey M. | Microscale lyophilization and drying methods for the stabilization of molecules |
US7004928B2 (en) * | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US20030176854A1 (en) * | 2002-03-11 | 2003-09-18 | Alcon, Inc. | Implantable drug delivery system |
US20040121486A1 (en) * | 2002-08-16 | 2004-06-24 | Uhland Scott A. | Controlled release device and method using electrothermal ablation |
US20040082937A1 (en) * | 2002-09-04 | 2004-04-29 | Dennis Ausiello | Method and device for the controlled delivery of parathyroid hormone |
US20040106914A1 (en) * | 2002-09-23 | 2004-06-03 | Coppeta Jonathan R. | Micro-reservoir osmotic release systems and microtube array device |
US20040106953A1 (en) * | 2002-10-04 | 2004-06-03 | Yomtov Barry M. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
US20040127942A1 (en) * | 2002-10-04 | 2004-07-01 | Yomtov Barry M. | Medical device for neural stimulation and controlled drug delivery |
US20040106904A1 (en) * | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
US20050050859A1 (en) * | 2003-07-17 | 2005-03-10 | Coppeta Jonathan R. | Low temperature methods for hermetically sealing reservoir devices |
US20050055014A1 (en) * | 2003-08-04 | 2005-03-10 | Coppeta Jonathan R. | Methods for accelerated release of material from a reservoir device |
US20050100937A1 (en) * | 2003-09-11 | 2005-05-12 | Holmes Elizabeth A. | Medical device for analyte monitoring and drug delivery |
US20050096587A1 (en) * | 2003-11-03 | 2005-05-05 | Santini John T.Jr. | Medical device for sensing glucose |
US20050267440A1 (en) * | 2004-06-01 | 2005-12-01 | Herman Stephen J | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402678B2 (en) * | 2009-07-27 | 2016-08-02 | Novoxel Ltd. | Methods and devices for tissue ablation |
US20120123401A1 (en) * | 2009-07-27 | 2012-05-17 | Nova-b Ltd. | Methods and devices for tissue ablation |
US10327832B2 (en) | 2009-07-27 | 2019-06-25 | Novoxel Ltd. | Methods and devices for tissue ablation |
US9024394B2 (en) | 2013-05-22 | 2015-05-05 | Transient Electronics, Inc. | Controlled transformation of non-transient electronics |
US10702328B2 (en) | 2013-12-18 | 2020-07-07 | Novoxel Ltd. | Devices and methods for tissue vaporization |
US11291498B2 (en) | 2013-12-18 | 2022-04-05 | Novoxel Ltd. | Methods and devices for thermal tissue vaporization and compression |
US11083515B2 (en) | 2013-12-18 | 2021-08-10 | Novoxel Ltd. | Methods and devices for thermal tissue vaporization and compression |
US9798886B2 (en) | 2015-07-08 | 2017-10-24 | International Business Machines Corporation | Bio-medical sensing platform |
WO2017079758A1 (en) * | 2015-11-06 | 2017-05-11 | Bkr Ip Holdco Llc | Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device |
US11268927B2 (en) | 2016-08-30 | 2022-03-08 | Analog Devices International Unlimited Company | Electrochemical sensor, and a method of forming an electrochemical sensor |
US10620151B2 (en) | 2016-08-30 | 2020-04-14 | Analog Devices Global | Electrochemical sensor, and a method of forming an electrochemical sensor |
EP3321899A1 (en) * | 2016-11-10 | 2018-05-16 | Therasolve NV | Electronic communication unit for an adhesive patch |
US10933029B2 (en) | 2017-03-24 | 2021-03-02 | E Ink California, Llc | Microcell systems for delivering active molecules |
US10646454B2 (en) | 2017-03-24 | 2020-05-12 | E Ink California, Llc | Microcell delivery systems including charged or magnetic particles for regulating rate of administration of actives |
EP3421080A1 (en) * | 2017-06-28 | 2019-01-02 | Fundación Tecnalia Research & Innovation | Device and method for controlled and monitored transdermal delivery of active agents and use thereof |
JP2020527411A (en) * | 2017-07-21 | 2020-09-10 | インターナショナル・ビジネス・マシーンズ・コーポレーションInternational Business Machines Corporation | Liquid delivery device and method of delivering liquid |
US20200032925A1 (en) * | 2017-07-21 | 2020-01-30 | International Business Machines Corporation | Fluid delivery device with hydrophobic surface |
JP7146319B2 (en) | 2017-07-21 | 2022-10-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Liquid delivery device and method of delivering liquid |
US11534585B2 (en) * | 2017-07-21 | 2022-12-27 | International Business Machines Corporation | Fluid delivery device with hydrophobic surface |
WO2019099323A1 (en) * | 2017-11-14 | 2019-05-23 | E Ink California, Llc | Microcell systems for delivering hydrophilic active molecules |
US11266832B2 (en) | 2017-11-14 | 2022-03-08 | E Ink California, Llc | Electrophoretic active delivery system including porous conductive electrode layer |
US11022579B2 (en) | 2018-02-05 | 2021-06-01 | Analog Devices International Unlimited Company | Retaining cap |
US11959876B2 (en) | 2018-02-05 | 2024-04-16 | Analog Devices International Unlimited Company | Retaining cap |
US11938215B2 (en) | 2019-11-27 | 2024-03-26 | E Ink Corporation | Method for operating a benefit agent delivery system comprising microcells having an electrically eroding sealing layer |
US11938214B2 (en) | 2019-11-27 | 2024-03-26 | E Ink Corporation | Benefit agent delivery system comprising microcells having an electrically eroding sealing layer |
US11648215B2 (en) | 2020-10-29 | 2023-05-16 | E Ink California, Llc | Microcell systems for delivering hydrophilic active molecules |
US11896723B2 (en) | 2020-10-29 | 2024-02-13 | E Ink Corporation | Microcell systems for delivering benefit agents |
Also Published As
Publication number | Publication date |
---|---|
WO2006015299A2 (en) | 2006-02-09 |
US7537590B2 (en) | 2009-05-26 |
WO2006015299A3 (en) | 2006-05-04 |
US20060024358A1 (en) | 2006-02-02 |
WO2006015299A9 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7537590B2 (en) | Multi-reservoir device for transdermal drug delivery and sensing | |
US20210169822A1 (en) | Transdermal drug delivery method and system | |
US7534241B2 (en) | Micro-reservoir osmotic release systems and microtube array device | |
CA2258898C (en) | Microchip drug delivery devices | |
JP5460538B2 (en) | Transdermal drug delivery patch system, method of making the system and method of using the system | |
US7070590B1 (en) | Microchip drug delivery devices | |
US8673346B2 (en) | Transdermal drug delivery method and system | |
US6132755A (en) | Transcorneal drug-release system | |
US20050267440A1 (en) | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant | |
US20050055014A1 (en) | Methods for accelerated release of material from a reservoir device | |
Gurman et al. | Clinical applications of biomedical microdevices for controlled drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |